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ABSTRACT 
 
COMING FULL CIRCLE: EPITHELIAL PLASTICITY AND  
THE NATURAL HISTORY OF METASTASIS 
Nicole Marie Aiello 
Ben Z. Stanger 
 
The primary cause of cancer-related deaths is metastasis— the spread of cancer cells to 
distant organs— and yet the mechanisms underlying this process remain elusive due to the 
difficulty in detecting early metastatic events, which are rare, stochastic and microscopic. To 
investigate the cellular and molecular mechanisms of metastasis, I utilized an autochthonous 
mouse model of pancreatic cancer (KPCY) in which all tumor cells are genetically labeled with 
yellow fluorescent protein (YFP). The YFP lineage label allows for the detection and isolation of 
disseminated tumor cells as they delaminate from epithelial structures within the primary tumor, 
invade into the stroma and circulation, and colonize distal organs. Using this system, I 
characterized the development of metastatic lesions from single disseminated cells to grossly 
macroscopic lesions in the murine liver. I found that gross metastases closely resembled primary 
tumors in terms of differentiation and microenvironment— these large lesions are well 
differentiated, containing primarily epithelial tumor cells, and accumulate stroma consisting of 
myofibroblasts, leukocytes and extracellular matrix (ECM). In contrast, single disseminated cells 
tend to be poorly differentiated and lack any association with stromal cells, and must build up a 
microenvironment around them as they grow. Despite the presumably protective stroma 
surrounding large lesions, gross metastasis was significantly reduced with chemotherapy, while 
single cells were unaffected. Interestingly, residual lesions were enriched for epithelial features, 
suggesting that EMT confers chemosensitivity in this context. I also used the KPCY model to 
investigate the molecular mechanisms of epithelial-mesenchymal transition (EMT), which is 
widely considered to be the first step in the metastatic cascade. The YFP lineage label made it 
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possible to identify and isolate tumor cells that have undergone EMT for transcriptional profiling. 
Surprisingly, I found that in a majority of pancreatic tumors, conventional transcriptional 
repressors were not involved in EMT. Although a mesenchymal transcriptional program was 
significantly enriched in cells that had undergone this “non-canonical” mechanism of EMT, the 
epithelial program was downregulated at the protein level by a mechanism involving protein 
internalization. Because cells retain both epithelial and mesenchymal properties during non-
canonical EMT, this phenomenon represents an attractive explanation for the ability of tumor cells 
to cycle between epithelial and mesenchymal states and adapt to the changing microenvironment 
on their way to metastatic sites. The journey from primary tumor to metastatic site requires cancer 
cells to overcome many obstacles and a better understanding of how they navigate the numerous 
steps of the metastatic cascade could open the door to desperately needed anti-metastatic 
therapies. 
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CHAPTER 1: Introduction  
 
Biology of pancreatic ductal adenocarcinoma 
 Pancreatic ductal adenocarcinoma (PDAC) is the most common form of 
pancreatic cancer and also the most deadly, with a five-year survival rate of only 7.7%1. 
The poor prognosis for PDAC patients can be attributed to frequent and widespread 
dissemination, chemoresistance and a lack of early detection methods. The vast majority 
of cases present with metastasis and are thus ineligible for surgery, the only known cure 
for PDAC2,3. Even those who receive surgery have an extremely high (90%) rate of 
recurrence4 and 70% of PDAC patients die from metastatic disease5, highlighting the 
need for therapies that can prevent or target metastasis.  
Pathology 
The most common lesions preceding PDAC are pancreatic intraepithelial 
neoplasia (PanINs), which are microscopic and characterized by ductular architecture. 
As PanINs increase in grade from 1-3, they acquire nuclear atypia and cytologic 
abnormalities until finally progressing to frank, locally invasive malignancy6. Intraductal 
papillary mucinous neoplasia (IPMN) and mucinous cystic neoplasia (MCN) can also 
evolve into PDAC but at a lower frequency compared to PanINs7. PDAC tumors are 
characterized by the accumulation of desmoplasia, which consists of various stromal cell 
populations such as leukocytes and fibroblasts, as well as numerous extracellular matrix 
components8. Unlike most solid cancers, PDAC is typically hypovascular and poorly 
perfused, which, in addition to the dense stroma, is thought to contribute to the failure of 
drug delivery to these tumors9-11. However, it is not clear whether the microenvironment 
plays a similar role in chemoresistance at metastatic sites. 
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Genetics 
PDAC is relatively homogenous in terms of driver mutations: over 90% of PDAC 
tumors harbor activating mutations in the oncogene Kras12, pointing to the RAS pathway 
as a critical gatekeeper of pancreatic tumorigenesis. Kras is a GTPase involved in the 
early steps of the signal transduction cascades activated by various growth factors. 
Mutations in the Kras gene frequently occur at codon 12 but are also found at codons 13 
and 61, all of which cause the protein product to be constitutively active. In addition to 
RAS, commonly altered signaling pathways include Hedgehog, TGF-β, WNT, apoptosis, 
regulation of G1/S transition, chromatin modification, DNA damage repair and axon 
guidance13,14. Subsequent mutations of tumor suppressors involved in these pathways, 
such as Tp53, Smad4 or Cdkn2a, are thought to be necessary for tumor progression15,16. 
On average, PDAC tumors possess significantly fewer somatic mutations compared to 
other cancer types such as breast and colorectal13. 
Subtypes 
 PDAC tumors can be stratified into both genetic and transcriptional subtypes. 
Whole genome sequencing and copy number variation have revealed four PDAC 
subtypes based on chromosome structural variation: stable, locally rearranged, 
scattered and unstable14. “Stable” tumors exhibit the fewest structural variation events 
(<50) but often exhibit aneuploidy, indicating defects in mitosis. “Locally rearranged” 
tumors are characterized by a single focal event, usually a large amplification or deletion 
or the fusion of two neighboring chromosomes. “Scattered” tumors exhibit a moderate 
level of chromosomal rearrangements while “unstable” tumors possess more than 200 
structural variation events and exhibit the highest genomic instability of all subtypes.  
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Transcriptional PDAC subtypes have been identified and corroborated by three 
independent groups. Using microarray data from patient samples and established 
human and murine PDAC cell lines, Collisson et al. were the first to stratify tumors into 
three subtypes: classical, exocrine and quasi-mesenchymal17. Classical tumors are 
moderate to well differentiated (i.e. exhibit epithelial histology) and tend to be sensitive to 
erlotinib, an EGFR inhibitor. The exocrine subtype is characterized by high expression of 
pancreatic enzyme genes and, like classical tumors, tends to be more differentiated in 
terms of histology. Quasi-mesenchymal tumors are often poorly differentiated, express 
high levels of mesenchyme-related genes and are sensitive to gemcitabine, the standard 
of care for PDAC. Using RNA-sequencing, Bailey et al. uncovered essentially the same 
PDAC subtypes plus an additional one in a panel of 96 human PDAC tumors: pancreatic 
progenitor (Collisson’s classical), aberrantly differentiated endocrine exocrine (ADEX; 
Collisson’s exocrine), squamous (Collisson’s quasi-mesenchymal) and immunogenic18. 
Most recently, Moffitt et al. utilized virtual microdissection to bioinformatically separate 
tumor and stromal gene expression in PDAC microarray data and identified two tumor 
subtypes, classical and basal-like, which closely resemble Collisson’s classical and 
quasi-mesenchymal subtypes, respectively19. Thus, there is clear consensus on the 
existence of at least two distinct PDAC subtypes that differ in histology, drug sensitivity 
and gene expression. 
Treatment 
There are limited options for PDAC treatment, with only a handful of FDA-
approved chemotherapeutic regimens. The standard of care for the last fifteen years has 
been gemcitabine, a nucleoside analog that causes apoptosis by inhibiting DNA 
replication20. More recently, clinical trials have attempted to combine gemcitabine with 
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other drugs, but few have represented improvements21. One successful combination, 
gemcitabine plus the microtubule inhibitor nab-paclitaxel, increased median overall 
survival by 1.8 months and is considered the new standard of care22. Another more 
aggressive four-drug regimen consisting of fluorouracil, irinotecan, oxaliplatin, and 
leucovorin (FOLFIRINOX) also increases median overall survival compared to 
gemcitabine alone (11.1 months vs. 6.8 months, respectively) but is used less frequently 
because of its side effects23. For patients with resectable disease, one of these drug 
combinations is usually given as adjuvant therapy after surgery, however most develop 
distant recurrence24-26, suggesting that nearly all PDAC patients have occult 
micrometastatic disease. There are ongoing clinical trials testing the efficacy of 
neoadjuvant therapy to reduce primary tumor size and involvement and target 
micrometastatic disease early on. For most patients, surgery is not an option so they 
must rely on aggressive chemotherapy, sometimes combined with radiation, to control 
the disease2. Despite recent advances, the five-year survival rate for those eligible for 
surgery, have locally advanced disease and metastatic disease are 29.3%, 11.1% and 
2.6% respectively1. Thus there is a critical need to understand and target 
chemoresistance at primary as well as metastatic sites. 
Metastasis 
 During the metastatic cascade, tumor cells break off from epithelial structures as 
either single cells or clusters, intravasate into the circulation, lodge in the capillary beds 
of distant organs and extravasate into the parenchyma where they grow into larger 
lesions27. Eighty percent of PDAC patients present with locally advanced or metastatic 
disease1, with dissemination primarily to the lymph nodes, liver, peritoneum, diaphragm 
and lung28. It was once thought that a tumor’s pattern of metastatic colonization reflected 
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blood flow and biomechanics, however in 1889 Paget’s “seed and soil” hypothesis 
completely upended this idea29. Paget postulated that tumors “seed” organs that are 
conducive to growth (i.e. fertile soil). It is now clear that not only do tumor cells 
selectively seed organs, but they also “fertilize” the soil to generate a receptive pre-
metastatic niche30-34. 
Gross metastatic lesions typically resemble the primary tumor they arose from 
histologically, which in the case of PDAC tend to be epithelial in nature35-37. However 
epithelial cells are not particularly motile or invasive, so it has been postulated that 
metastasizing cells must go through epithelial-mesenchymal transition (EMT) to escape 
from the primary tumor and then the reverse process, mesenchymal-epithelial transition 
(MET) during colonization. There is precedent for this paradigm in embryogenesis, 
during which multiple rounds of EMT/MET are necessary for the formation of the three 
germ layers and various organs38. Numerous studies have demonstrated that EMT 
increases tumor cell dissemination but not metastatic colonization, while epithelial tumor 
cells have high colonization potential39-41.  
Common themes in embryogenesis and cancer 
The process of embryogenesis requires precise spatial and temporal activation of 
developmental signaling pathways. Re-activation of these embryonic signals in adult 
cells, a consequence of mutations and epigenetic remodeling, is a characteristic feature 
of cancer. Key developmental signaling pathways – including the Wnt, Hedgehog, and 
Notch pathways – are frequently dysregulated in cancer and participate in all stages of 
tumor progression, from initiation and maintenance to metastatic spread and growth at 
distant sites (Figure 1.1).  
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During development, Wnt signaling is involved in cell fate specification, 
proliferation and migration, and in the adult this pathway is involved in maintaining 
homeostasis in tissues such as the intestine, where Wnt signaling is critical for stem cell 
function42,43. There are three known Wnt pathways: canonical, which regulates gene 
expression, and two non-canonical pathways that regulate planar cell polarity and 
calcium flux44. In this review we have focused on canonical Wnt signaling because this is 
the most frequently implicated Wnt pathway in cancer. As depicted in Figure 1.1A, in the 
absence of a Wnt signal, the canonical Wnt effector beta-catenin (CTNNB) is 
continuously phosphorylated and targeted for degradation by glycogen synthase kinase-
3 (GSK3), which is stabilized when complexed with adenomatous polyposis coli (APC) 
and Axin. In response to Wnt glycoproteins, which signal through Frizzled receptors 
(FRZ) and their coactivators low-density lipoprotein receptor-related proteins 5 and 6 
(LRP), Axin binds FRZ and is unable to stabilize the APC/GSK3/CTNNB complex, 
freeing CTNNB to enter the nucleus and facilitate the transcriptional activity of the T-cell 
specific transcription factor (TCF) and lymphoid enhancer binding factor (LEF) family44. 
Canonical Wnt signaling is active in nearly all developing tissues and plays a critical role 
in body axis patterning45, stem cell maintenance and lineage specification46,47. In the 
adult, hyper-activation of the Wnt pathway – typically due to loss of the tumor suppressor 
protein APC – represents the first step in colorectal tumorigenesis48. Ligand-independent 
activation of CTNNB is a more common alteration in cancers outside the gut, especially 
in endometrioid ovarian cancer, hepatoblastoma and Wilms’ tumors49,50.  
The Hedgehog (HH) pathway, like the Wnt pathway, plays a critical role in the 
development of many organs including but not limited to the patterning of the central 
nervous system (CNS), tooth development and limb formation51-53. HH ligands, of which 
there are three including Sonic hedgehog (SHH), Indian hedgehog (IHH) and Desert 
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hedgehog (DHH), act as morphogens to direct left-right asymmetry and cell fate 
decisions and pattern developing tissues54. In the absence of HH ligands, the 
transmembrane protein Patched (PTC) indirectly facilitates the degradation of GLI-family 
zinc finger proteins (GLI) by blocking Smoothened (SMO) activity. In the presence of HH 
ligands, PTC is unable to inhibit SMO, which stabilizes GLI and allows it to translocate 
into the nucleus where it acts as a transcription factor (Figure 1.1B)55. In the pathogenic 
context, activation of the HH pathway can lead to basal cell carcinoma (BCC) (a type of 
skin cancer)56 or to the recruitment of a fibroblast-rich stroma in pancreatic cancer57,58.  
The Notch pathway is similarly involved in embryonic cell fate decisions; 
specifically, it is critical for the development of organs including but not limited to the 
CNS, pancreas, bone, and heart59. This pathway is activated by juxtacrine signaling 
between the Notch receptor on the receiving cell and Notch ligands including Delta-like 
(DLL) and Jagged (JAG) on the signaling cell. Upon binding of Notch ligands to the 
receptor, gamma-secretase (γ-SEC) cleaves the intracellular Notch domain (NICD), 
allowing it to enter the nucleus and facilitate the transcriptional activity of Recombination 
signaling binding protein for kappa J region (RBPJ) (Figure 1.1C)60. Notch’s role in tumor 
progression seems to be context-dependent, as the pathway can act as an oncogene in 
some settings (e.g. breast cancer and T-cell leukemia) or as a tumor suppressor gene in 
others (e.g. skin cancer)61-63, although the latter may be through a non-cell autonomous 
mechanism64. Other cellular signaling pathways in addition to Wnt, HH and Notch play 
critical roles in cell fate specification and migration during embryogenesis and have also 
been implicated in cancer invasion and metastasis. These include the fibroblast growth 
factor (FGF) and transforming growth factor beta (TGFβ)/bone morphogenic protein 
(BMP) signaling pathways which will be discussed later in this section for their ability to 
promote cell migration and invasion in both the developmental and cancer contexts65-68. 
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Thus, the molecular cues used to pattern an embryo are harnessed by tumor cells to 
enhance growth, recruit stromal cells and coordinate spread from the primary tumor.  
A recurring motif in development is reciprocal signaling between neighboring cell 
populations; crosstalk that facilitates morphogenesis of the emerging tissue. Reciprocal 
signaling between developing epithelium and mesenchyme occurs repeatedly during 
embryogenesis and is critical for the formation of limbs, epidermal appendages, 
pancreas, lungs, kidney and other organs69-75. Carcinomas also contain a mixture of 
epithelium - cancer cells - and mesenchyme, which in the cancer context is known as 
stroma. The latter consists of leukocytes, fibroblasts, endothelium and lymphatic 
vessels, and collectively form what is known as the “tumor microenvironment” (TME). 
These cell populations engage in molecular crosstalk with cancer cells, which can effect 
cancer cell survival, proliferation and migration. An example is provided by pancreatic 
cancer. As touched upon above, pancreatic tumor cells secrete SHH, a HH ligand, which 
recruits fibroblasts to form the dense “desmoplastic” or fibrotic stroma of that cancer 
type57,76,77. The fibroblast-rich stroma of pancreatic cancer has been demonstrated to 
exert both pro- and anti-tumor effects. Although desmoplasia is known to impair drug 
delivery9-11, depletion of myofibroblasts using genetic and pharmacological methods 
results in increased tumor growth and metastasis58,78. Nonetheless, signaling between 
cancer cells and the stromal cells they recruit is a common theme in carcinoma 
progression. Through reciprocal interactions such as these, tumors build a non-
cancerous stroma that in turn influences cancer cell behavior. 
Embryogenesis entails dramatic morphological changes and cellular movements 
that are recapitulated within tumors. One of the most notable of these is epithelial to 
mesenchymal transition (EMT), a process in which epithelial cells lose their epithelial 
characteristics, including apical-basal polarity and cell-cell adhesion, and take on the 
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motile features of fibroblasts. The primary role of EMT is during embryonic development, 
where it is critical for gastrulation, and other developmental events; however, cancer 
cells exploit this property of increased motility to facilitate spread. During gastrulation, 
WNT, TGF-β and FGF orchestrate primitive streak formation by promoting EMT via the 
activation of transcription factors Snail and Twist65,79,80. These developmental EMT 
transcription factors (EMT-TFs) are also drivers of EMT and consequent metastasis in 
breast, pancreatic and colorectal cancers, among others81,82. EMT is again required later 
in development, for neural crest cell migration, and is facilitated by Snail, Slug (also 
known as Snail2), and the Zeb family of transcription factors; these too have been 
implicated in cancer cell invasion and dissemination83-85.  
The primary function of EMT-TFs is to transcriptionally repress epithelial genes 
and activate mesenchymal genes86. One classic EMT-TF target is E-cadherin (Cdh1), a 
critical regulator of epithelial identity and a component of adherens junctions where it 
interacts with catenins. E-cadherin is a calcium-dependent cell adhesion molecule that 
tethers epithelial cells closely together87. Loss of E-cadherin allows an epithelial cell to 
disengage from its neighbors and is considered a hallmark of EMT88. In addition to E-
cadherin, other epithelial proteins such as those within tight junctions (claudins and 
occludins) and the cytoskeleton (keratins) are also downregulated89-91. Concurrently, 
mesenchymal genes involved in cell motility and extracellular matrix interactions are 
switched on to facilitate invasion92. MicroRNAs (miRNA), including the miR-3493,94 and 
miR-200 families95-99, negatively regulate EMT-TFs to keep the EMT program in check. 
Alternative splicing, epigenetic modifications and post-translational regulation are 
layered on top of miRNA negative feedback loops, resulting in complex regulatory 
circuitry that controls the balance of EMT-promoting and -inhibiting factors86.  
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Fate mapping 
Once a cancer cell undergoes EMT it becomes indistinguishable from the 
surrounding non-cancerous stroma. Likewise, studying metastasis in vivo has been 
challenging, particularly in the context of a spontaneously-growing tumor because each 
of the events that occur during metastasis – from invasion through basement 
membranes to growth at distant sites – involve rare stochastic phenomena that are 
difficult to capture experimentally. Fate mapping, also known as lineage-labeling or 
lineage-tracing, was originally developed to visualize the fate of individual cells and their 
progeny, referred to as clones, during embryogenesis, but it has also proven useful for 
the study of tumor-initiating populations and dynamic cellular movements in the context 
of cancer. Early fate mapping experiments employed vital dyes, fluorescent dyes, or 
radio-labeling to mark a specific region, lineage, or even a single cell of an embryo and 
follow it throughout development as cells divide and migrate away from their original 
positions. These studies allowed embryologists to generate detailed fate maps for a 
number of model organisms, including frog, zebrafish and chick100-102.   
With the advent of site-specific recombinase technology such as the Cre-lox 
system it became possible to genetically label and track a cell lineage, facilitating fate 
mapping in mammals, which, unlike lower model organisms are not transparent and 
contain many more cells and lineages. Cre recombinase (Cre) recognizes specific DNA 
sequences (loxP sites) and targets these for recombination, which, depending on the 
orientation of the sites can result in deletion, inversion or translocation of intervening 
sequences103,104. Typically, loxP sites are used to delete regions of DNA, such as, for 
example, a gene of interest or a stop codon located upstream of a fluorescent reporter 
gene105. Cre expression can be restricted to specific cell types by altering upstream 
promoter elements, which permits spatial control of gene expression106. Thus the Cre-lox 
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system can be utilized to specifically and indelibly label tumor cells, allowing for the 
detection and isolation of cancer cells that have undergone EMT, intravasated into the 
circulation and colonized distant organs. 
Cell-of-origin 
A pressing issue in cancer biology is the elucidation of tumor-initiating cells or 
“cell-of-origin” in cancer: which cells in a normal tissue give rise to cancer? Given the 
robust self-renewal capacity of cancer cells, it is often assumed that cancers arise from 
resident, adult stem cells within tissues, and hence the concepts of “cell-of-origin” and 
“cancer stem cells” are often conflated. (The cancer stem cell hypothesis posits that a 
subset of cells within the tumor harbor most of the tumor’s long-term self-renewal 
capacity, a concept quite distinct from the cell-of-origin, which merely points to the cell 
type within a tissue most likely to be transformed by the initiating mutation). Importantly, 
because cancer cells can, in principle, acquire stem cell properties as a consequence of 
mutation or epigenetic remodeling, they need not arise from stem cells. The ability of 
tumors to emerge in tissues where it is questionable whether stem cells exist (e.g. the 
kidney) is further evidence that cancers can arise from fully differentiated cells.  
Lineage tracing has been a powerful tool to identify stem cell populations in 
embryonic and adult tissues, and the same approach has now been used to identify 
tumor-initiating cells in cancer (Figure 1.2). Several years ago, Lgr5 – a Wnt-target gene 
– was identified as a marker of intestinal stem cells, as Lgr5+ cells labeled with Cre-
based technology durably gave rise to all the differentiated cell types of the intestinal villi 
as well as more Lgr5+ cells107,108. Building on this approach, Barker and colleagues 
(2009) used additional Cre-based tools to delete the tumor suppressor gene Apc in 
either the stem cell compartment (using Lgr5-Cre) or the non-stem cell “transient 
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amplifying” compartment--capable of short-term self-renewal only-- using Ah-Cre. While 
Apc deletion in the stem cells resulted in adenomas (premalignant lesions) that exhibited 
unimpeded growth, Apc deletion in the transient amplifying cells resulted in 
microadenomas (tumors less than 10mm in diameter) whose growth rapidly 
stalled109109109. This result suggested that intestinal stem cells are more competent than 
their transient-amplifying cell progeny – in the context of an APC mutation – to form 
tumors.  
At present, lineage tracing offers the most robust method of addressing the 
cancer stem cell hypothesis in vivo. By using inducible Cre systems such as CreER and 
titrating the dose of tamoxifen, one can limit recombination to rare, sparse cells within a 
tissue, providing the resolution to identify clonal populations. Utilizing this concept, 
Driessens and colleagues (2012) were able to identify cancer stem cells and their 
progeny in a chemical-induced carcinogenic model of squamous cell carcinoma (SCC). 
Using a lineage labeling system driven by Keratin 14 (K14)-CreER which marks basal 
epithelial cells within the epidermis, the authors found that only 20% of these cells were 
capable of generating a large clonal population of pre-malignant papilloma cells. 
However, when the authors allowed these papillomas to progress to malignant SCC, the 
tumors were became poorly differentiated and exhibited a much higher frequency of 
long-term replicative cells, suggesting that in the transition from benign to malignant the 
cancer stem cell/differentiated progeny hierarchy starts to fall apart110. 
Such lineage tracing experiments support the general notion that cancer is the 
result of having the “right” mutations in the “right” cell at the “right” time. In other words, 
certain cell populations (stem cells or non-stem cells) might be susceptible to the 
oncogenic effects of certain gene mutations that have no effect in other cell populations. 
Additional factors, such as the local environment (e.g. inflammation), could contribute to 
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the susceptibility or resistance of various cell types to the cancer-causing effects of a 
given mutation. Similar lineage tracing experiments have identified cells-of-origin in a 
number of contexts111-115. From these studies, it appears that in some cases tumors arise 
from resident tissue stem cells (e.g. intestinal tumors and basal cell carcinomas), 
whereas in other cases it appears that tumors can arise from fully differentiated cells 
(e.g. pancreatic tumors, cholangiocarcinomas, gliomas). 
Clonal heterogeneity and tumor evolution 
Genomic analyses have confirmed that tumors are composed of numerous “sub-
clones,” or clones with distinct mutations in addition to the original tumor-driving 
mutation(s)116,117. Such tumor heterogeneity is a consequence of “clonal evolution,” a 
process whereby cells within a cancer can acquire different mutations that lead them to 
be genetically and phenotypically distinct. A recent study has suggested that interactions 
between different sub-clones might drive tumor growth118, suggesting that heterogeneity 
might not be merely a byproduct of clonal evolution but could also underlie key features 
of tumor biology. 
Lineage tracing lends itself to the study of clonal evolution and the complex 
relationships between clonal populations. One useful tool has been the “Confetti” mouse, 
a strain in which cells are labeled with one of four fluorescent colors upon activation of 
Cre activity119. The system relies on the fact that Cre mediates different recombination 
events depending upon the orientation of LoxP sites: if LoxP sites are oriented in the 
same direction, the DNA sequence between them will be excised, if they are oriented in 
opposite directions, the gene between them will be inverted, and if they are located on 
separate chromosomes, Cre will mediate a translocation120. Within the Confetti allele, 
four fluorescent protein genes are flanked by LoxP sites and oriented in such a way that 
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excision or inversion results in the (somewhat) random expression of one of the four 
lineage labels. Using this system, it has been possible to identify “bottlenecks” during the 
clonal evolution of a tumor in vivo. For example, premalignant progression in pancreatic 
cancer is associated with a shift from acinar-to-ductal metaplasia (ADM), which are 
polyclonal, to more advanced pancreatic intraepithelial neoplasia (PanIN), which are 
monoclonal. This model has also revealed differences in metastatic potential between 
different tumor sub-clones, providing evidence for inter-clonal cooperation during tumor 
dissemination121. 
Lineage tracing has also provided insight into clonal evolution following 
chemotherapeutic selective pressures. Using a Cre-inducible mouse model of 
glioblastoma, for example, Chen et al. found that Nestin+ adult neural stem cells 
genetically labeled with green fluorescent protein (GFP) made up only a small fraction of 
naïve tumor, but upon treatment with temozolomide, an alkylating agent that is used to 
treat some brain cancers, these cells and their progeny expanded to become the most 
abundant tumor clone122. Similarly, in a mouse model of SHH-driven medulloblastoma, 
rare quiescent Sox2+ adult neural stem cells were found to be resistant to anti-mitotic 
and SHH-targeted therapy and responsible for recurrence after treatment123. These 
studies offer an explanation for why single therapies typically fail-- there is almost 
inevitably a resistant tumor subclone that will repopulate the tumor. The best strategy 
likely involves using multiple therapies targeting different pathways to reduce the chance 
of a single resistant subclone growing out. 
EMT and invasion 
It is comparatively easy to identify cells undergoing EMT during embryogenesis, 
as whole cell populations (e.g. the epiblast) can be observed to undergo a 
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transformation from an epithelial sheet to highly migratory fibroblast-like cells. However, 
it has proven to be exceptionally difficult to study cancer-associated EMT in vivo, 
because once a cancer cell undergoes EMT it becomes indistinguishable from the 
surrounding non-cancerous stroma. Likewise, studying metastasis in vivo has been 
challenging, particularly in the context of a spontaneously-growing tumor because each 
of the events that occur during metastasis – from invasion through basement 
membranes to growth at distant sites – involve rare stochastic phenomena that are 
difficult to capture experimentally.  
Again, lineage tracing has proven to be a useful technique in studying these 
processes. For example, by introducing a yellow fluorescent protein (YFP) lineage label 
into a well-established genetically engineered mouse model (GEMM) of pancreatic 
cancer, it became possible to unambiguously identify cells that had undergone EMT, as 
such cells still bore the lineage marker confirming their epithelial origins, despite 
acquiring a mesenchymal phenotype124. Lineage tracing has also been used to elucidate 
the dynamics of metastasis. For example, Aytes and colleagues (2013) used a YFP 
reporter in the context of a mouse model of prostate cancer to determine the temporal 
occurrence of lung metastasis: at one month post-induction, rare single YFP+ cells could 
be observed in the lung; at two months, YFP+ micrometastases were evident; and by 
three months, gross metastases were found in 100% of animals125. Similar observations 
have been made in pancreatic cancer, where lineage tracing has enabled the 
examination of the rare events involved in metastatic growth, down to single cell 
resolution.  
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Mouse models of pancreatic ductal adenocarcinoma 
Numerous mouse models of PDAC exist, and they all share the common theme 
of Kras deregulation and closely recapitulate the human disease in terms of progression 
from PanIN to PDAC, frequency and location of metastasis and poor response to 
chemotherapy. In each of these models, Cre-mediated recombination of loxP-stop-loxP 
(LSL) KrasG12D (a constitutively active mutant) is driven by one of three pancreas-specific 
promoters: Pdx1, Ptf1a (also called p48) or Ela1126. Pdx1 and Ptf1a are both expressed 
by pancreatic progenitor cells during development, however Pdx1 becomes restricted to 
endocrine cells in the adult pancreas while Ptf1a expression is limited to acinar cells of 
the exocrine compartment127. On the other hand, Ela1 is expressed only in mature acinar 
cells128. Mutant Kras alone drives pancreatic tumorigenesis in only a fraction of mice and 
with a long latency (>1 year)129, so many models also employ floxed or dominant 
negative (DN) tumor suppressor alleles such as Tp53, Smad4 or Cdkn2a (lost in 50-95% 
of human PDAC tumors)126. Loss of one of these tumor suppressors in addition to the 
expression of a constitutively active mutant Kras dramatically shortens tumor latency to 
2-5 months and increases penetrance126. Addition of a genetic lineage label such as 
LSL-Rosa26YFP/YFP allows for the visualization of rare, stochastic events such as EMT 
and early metastatic colonization. Using the KPCY model (Pdx1-Cre, LSL-KrasG12D, 
Tp53fl/+, LSL-Rosa26YFP/YFP), our lab previously demonstrated that EMT does indeed 
occur in living tumors and that there is evidence of dissemination to the liver even at pre-
neoplastic stages124. 
At present, a diagnosis of metastatic pancreas cancer is essentially a death 
sentence; thus there is a dire need for effective anti-metastatic treatments. However, to 
develop new therapies a basic understanding of the mechanisms driving metastasis is 
necessary. The molecular mechanisms underlying cancer cell EMT in vivo are still poorly 
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understood; much of what we know about EMT has been revealed by forcing cancer cell 
lines to undergo EMT through Tgf- treatment or overexpression of known EMT-TFs, 
which may not accurately reflect spontaneous EMT in living tumors. Another poorly 
understood aspect of metastasis is that of colonization: it is unclear how single 
disseminated cells develop into large metastatic lesions that closely resemble the 
original primary tumor. A stronger grasp of the mechanisms of spontaneous EMT and 
the natural history of metastatic colonization would open up new avenues for the 
prevention and treatment of metastasis. My thesis work sheds light on these processes 
using a lineage labeled mouse model of PDAC, which allowed me to isolate and 
transcriptionally profile of tumor cells that have undergone EMT in vivo and to detect 
occult micro-metastases and follow their development. 
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Chapter 1 Figures and Figure Legends 
 
 
 
Figure 1.1: Developmental pathways are frequently activated in cancer. WNT, HH 
and NOTCH pathways are involved in many aspects of embryogenesis, including, but 
not limited to, patterning, cell fate specification, proliferation and stem cell maintenance. 
Dysregulation of each of these signal transduction pathways has been implicated in 
tumor initiation. In each case, the pathway is activated upon binding of a ligand to a 
receptor on the plasma membrane. This sets off a cascade of events allowing an 
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effector to translocate to the nucleus and affect gene transcription. Pathway genes that 
are typically inactivated in cancer are highlighted in red; genes that are frequently 
hyperactivated in cancer are shown in green. WNT, wingless-type MMTV integration 
site; FRZ, Frizzled; LRP, low-density lipoprotein receptor-related protein; APC, 
adenomatous polyposis coli; GSK3, glycogen synthase kinase-3; CTNNB, β-catenin; P, 
phosphorylation; TCF, T-cell-specific transcription factor; LEF, lymphoid enhancer 
binding factor; HH, hedgehog; PTC, patched; SMO, smoothened; GLI, GLI-family zinc 
finger; DLL, delta-like; JAG, jagged; NICD, notch intracellular domain; γ-sec, γ-
secretase; RBPJ, recombination signaling binding protein for kappa J region.  
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Figure 1.2: Use of lineage labeling to identify stem cells during development and 
tumor progression. Using inducible Cre-recombinase technology, cells within a lineage 
are sparsely labeled to provide the resolution necessary to identify clonal populations. 
After a short period of time, labeled progeny (shown in green) become apparent. If the 
original labeled cell is a genuine stem cell, the labeled clones will persist over the lifetime 
of the tissue (or tumor) because the stem cell is continuously self-renewing and 
producing differentiated daughter cells. If, on the other hand, the labeled clones are lost 
over time, the original labeled cell was most likely a transient amplifying cell, which is 
capable of short-term self-renewal but eventually becomes terminally differentiated, no 
longer contributing to the pool of cells. This test is not only useful for identifying stem 
cells and cancer stem cells but also for detecting drug-resistant clones. After sparse 
labeling and chemotherapy, drug-resistant clones will persist and begin to take up a 
much larger fraction of the tumor cell population, much like a stem cell. 
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CHAPTER 2: Metastatic progression is associated with 
dynamic changes in the local microenvironment 
 
Abstract 
Most cancer-associated deaths result from metastasis. However, it remains 
unknown whether the size, microenvironment, or other features of a metastatic lesion 
dictate its behavior or determine the efficacy of chemotherapy in the adjuvant 
(micrometastatic) setting. Here, we delineate the natural history of metastasis in an 
autochthonous model of pancreatic ductal adenocarcinoma (PDAC), using lineage 
tracing to examine the evolution of disseminated cancer cells and their associated 
microenvironment. With increasing size, lesions shift from mesenchymal to epithelial 
histology, become hypovascular, and accumulate a desmoplastic stroma, ultimately 
recapitulating the primary tumors from which they arose. Moreover, treatment with 
gemcitabine and nab-paclitaxel significantly reduces the overall number of metastases 
by inducing cell death in lesions of all sizes, challenging the paradigm that PDAC stroma 
imposes a critical barrier to drug delivery. These results illuminate the cellular dynamics 
of metastatic progression and suggest that adjuvant chemotherapy affords a survival 
benefit by directly targeting micrometastases. 
 
Introduction 
Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate of less than 
6%, a dismal outcome related to late detection and a high rate of spread at the time of 
diagnosis1,130. Hence, metastatic disease accounts for a majority of PDAC-related 
deaths, even for patients with resectable tumors and no evidence of metastasis at the 
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time of diagnosis2,5. However, the mechanisms by which tumor cells navigate the 
“metastatic cascade” – a gauntlet that requires cellular escape from the primary tumor, 
survival in the circulation, invasion into distal tissues and colonization (growth) in a 
foreign, potentially hostile microenvironment – remain poorly understood131. 
One process thought to facilitate metastasis is epithelial-mesenchymal transition 
(EMT), whereby epithelial cells lose their adhesive contacts with neighbors and take on 
the migratory phenotype of mesenchymal cells92. Although EMT is believed to play a role 
in the dissemination of carcinoma cells, it has also been observed that metastases tend 
to exhibit the epithelial histology of their parent primary tumors35,36,132. This has led to the 
idea that the reverse process – mesenchymal-epithelial transition (MET) – drives the 
formation of a more epithelial phenotype at metastatic sites133. Although several studies 
support the view that MET is critical for metastatic colonization39-41, evidence for this 
phenomenon is lacking from spontaneous tumor models.  
Like primary tumors, metastases are a conglomerate of cancer cells, stromal 
cells, and extracellular matrix (ECM). In primary pancreatic cancer, a particularly dense 
(desmoplastic) stroma containing leukocytes, fibroblasts, and ECM makes up a large 
portion of the tumor mass, while the density of blood vessels tends to be low8. Although 
macro-metastatic lesions of various cancers – including PDAC, ovarian and breast – 
also exhibit a dense stromal infiltrate, it remains unclear when during metastatic 
progression this re-establishment of the tumor microenvironment occurs. 
Here, we have taken advantage of a lineage-labeled autochthonous model of 
pancreatic cancer to carefully catalog the changes that occur within metastatic cells and 
their immediate microenvironment during metastatic colonization and growth. We report 
that the process is highly dynamic, as both tumor cells and the stroma undergo marked 
changes during progression from singly seeded cells to micro- and macro-metastases. 
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Furthermore, we show that treatment with gemcitabine and nab-paclitaxel results in 
killing of metastatic tumor cells despite the presence of an ostensibly protective 
microenvironment. These results provide insight into the process of metastatic 
colonization and challenge the hypothesis that stroma acts as a physical barrier to drug 
delivery. 
 
Results 
Lineage tracing permits detection of micro-metastases 
We began by characterizing metastatic PDAC lesions in KPCY mice – in which 
Cre-mediated recombination triggers mis-expression of mutant KrasG12D, deletion of one 
copy of p53, and activation of a YFP lineage label in pancreatic epithelial cells – allowing 
us to track tumor cells at the single cell level124. KPCY mice, like related mouse 
models134,135, exhibit a pattern of gross metastasis similar to the human disease, 
consisting of spread to liver (40.5% of mice), diaphragm (32.4%), lung (10.8%), 
peritoneum (5.4%) and kidney (2.7%) (n= 40). We confined our subsequent analysis to 
the liver as it is the most frequent site of metastasis. Lesions were binned into five size 
categories according to the number of YFP+ cells: single, nano (2-10 cells), micro (11-
100 cells), milli (101-1000 cells) and macro (greater than 1000 cells) (Fig. 2.1a). When 
examined microscopically, nearly all tumor-bearing KPCY mice exhibited single cells 
(95.6%) or nano-metastases (91.3%) in the liver, while a lower frequency of animals had 
micro-metastases (65.2%) or milli- and/or macro-metastases (39.1%) (n=23). Most 
metastatic lesions contained 100 or fewer cells, with nano- and micro-metastases being 
the most abundant (Fig. 2.1b). Detailed metastatic burden quantification for each animal 
is listed in Table 2.1. 
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 We next sought to determine baseline levels of proliferation and apoptosis within 
metastatic lesions. Surprisingly, proliferation rates (as measured by the percentage of 
Ki67+ cells within each lesion) were not significantly different across lesions of all five 
metastatic categories (11-19%) and were comparable to the primary tumor (Fig. 2.1c, 
Fig. 2.2a). These results were corroborated by staining for phospho-histone H3 (pH3), a 
marker of mitosis (Fig. 2.2b,e) and proliferating cell nuclear antigen (PCNA) (Fig. 2.2c,f). 
Apoptosis, as measured by the percentage of cleaved caspase-3 (CC3) positive cells 
within each lesion, was absent from single cells and rarely seen in nano-metastases 
(0.2% of cells within nano-metastases were CC3+). Primary tumors and larger lesions 
also exhibited low (~1%), albeit significantly higher levels of apoptosis compared to 
single cells (Fig. 2.1c; Fig. 2.2d). To determine if proliferation is also constant across 
lesions in human PDAC we stained matched primary tumors, gross metastases and 
micro-metastatic lesions from patients for Ki67 (Fig. 2.3a-d). We found that the rate of 
Ki67 positivity (mean ± SD) was not significantly different between primary tumors (2.1 ± 
1.9), gross metastases (5.4 ± 5.6) and micro-metastases (3.1 ± 5.9), similar to what we 
observed in mouse PDAC. These data suggest that metastatic cancer cells exhibit 
similar rates of proliferation regardless of lesion size. 
 
Metastatic lesions become more epithelial as they grow 
We next determined the epithelial-mesenchymal status of cells at various stages 
of metastatic growth by co-staining with a panel of epithelial and mesenchymal markers 
and the YFP lineage label. To identify tumor cells with epithelial characteristics, we used 
antibodies that recognize E-cadherin (ECAD) and Claudin-7 (CLDN7)82,89,136 and 
measured the percentage of YFP+ cells that exhibited positive staining as a function of 
lesion size. Compared to single cells and nano-metastases, in which fewer than half of 
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the cells were positive for these markers, metastases having 100 cells or more (milli- 
and macro-) exhibited rates of epithelial staining in the range of 60-80%, resembling 
primary tumors (Fig. 2.4a, b, e). A complementary pattern of staining was observed 
when antibodies against fibroblast-specific protein-1 (FSP1) or zinc finger E-box binding 
homeobox 1 (ZEB1) were used90,137, as milli- and macro-metastases exhibited reduced 
staining with these markers relative to nano-metastases (Fig. 2.4c, d, e). Comparing the 
frequency of epithelial (ECAD/CLDN7) cells to mesenchymal (FSP1/ZEB1) staining 
within each size group revealed that single cells and nano-metastases exhibited 
comparable frequencies of cells positive for these epithelial and mesenchymal markers; 
by contrast, larger lesions had a significantly greater fraction of epithelial cells (Fig. 2.5). 
These results are consistent with the notion that small metastatic lesions contain a 
higher percentage of cells that have undergone EMT, and that such cells revert to a 
more epithelial state, via MET, during colonization and growth. To determine whether 
this trend is also observed in human PDAC, we performed IHC on primary human PDAC 
tumors, gross liver metastases and microscopic liver metastases for CLDN7 and FSP1. 
Consistent with the murine data, CLDN7 staining was greater in primary tumors than 
micro-metastases while FSP1 staining was greater in micro-metastases compared to 
gross metastases and primary tumors (Fig. 2.6). Thus, in both mouse and human PDAC, 
metastatic cells appear to re-acquire an epithelial phenotype with increasing lesion size. 
 
Desmoplasia gradually accumulates at metastatic lesions  
 Desmoplasia – a dense infiltrate of non-cancerous stromal cells and extracellular 
matrix (ECM) components – is a hallmark of PDAC, where it is thought to promote tumor 
growth and act as a barrier to the effective delivery of chemotherapy138. Myofibroblasts, 
a subset of fibroblasts involved in wound healing and fibrosis, are among the most 
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prevalent stromal cell types in PDAC. To determine if and when myofibroblasts 
accumulate during metastatic growth, we stained metastatic livers for YFP and α-smooth 
muscle actin (αSMA). Importantly, and in contrast to a recent publication139, αSMA is 
specific to myofibroblasts and is never expressed in cancer cells that have undergone 
EMT (under review). Nearly all metastatic lesions consisting of 10 or more cells were in 
direct contact with myofibroblasts, while smaller lesions were less frequently associated, 
especially single cells (Fig. 2.7a, b). In particular, myofibroblast recruitment seemed to 
occur at the nano-metastasis stage, as there was a direct correlation between the 
number of cells present in a lesion (from 2 to 10) and their association with 
myofibroblasts (Fig. 2.8a). Additionally, the number of associated myofibroblasts 
significantly increased with lesion size, as demonstrated by an increase in αSMA+ area 
at larger lesions (Fig. 2.7c). 
 ECM components can be deposited by myofibroblasts or by tumor cells 
themselves (following EMT), and contribute to the desmoplastic reaction in PDAC8,140. 
Collagen I (COL1), hyaluronic acid (HA), fibronectin (FN) and secreted protein acidic and 
rich in cysteine (SPARC) represent the most abundant constituents in PDAC140,141. With 
the exception of FN density, which peaked at intermediate-sized micro-metastases, all 
other ECM components exhibited an increase as lesions grew (Fig. 2.7d-g, Fig. 2.8b-e) 
with the most dramatic change being the levels of SPARC present in all lesions as 
compared to single cells (Fig. 2.7f). These results demonstrate that the desmoplastic 
response begins at the nano-metastasis stage and that most stromal components 
increase in density as a function of lesion size. We also sought to determine whether 
ECM accumulation occurs during metastatic growth in human PDAC. We performed IHC 
for FN on primary human PDAC tumors, gross liver metastases and microscopic liver 
metastases and found that FN expression is higher in micro-metastases compared to 
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primary tumors (Fig. 2.9), consistent with the pattern of FN deposition observed in KPCY 
metastases. 
 In addition to myofibroblasts and ECM, pancreatic neoplasia is accompanied by 
a robust infiltration of leukocytes, particularly myeloid cells, which can comprise more 
than half of the cells within a tumor142,143. We thus determined how leukocyte populations 
change during metastatic progression by staining livers for CD45 (pan-leukocyte), F4/80 
(macrophages), Gr-1 (myeloid-derived suppressor cells [MDSCs]), CD3 (T lymphocytes) 
and YFP (Fig. 2.10). Although the number of macrophages, MDSCs and leukocytes in 
general was increased in uninvolved areas of metastatic livers compared to control 
(Pdx1-Cre; RosaYFP) livers (Fig. 2.10a-e), only MDSCs showed a significant association 
with metastatic lesions, specifically nano-, micro- and milli-metastases (Fig. 2.10h,m). In 
contrast, T lymphocyte density, which was lower overall compared to the other leukocyte 
subsets, was unchanged between metastatic and control livers and across metastatic 
lesions (Fig. 2.10j,n). These results suggest that the presence of a primary pancreatic 
tumor causes a marked increase in certain leukocyte subsets in the liver, only MDSCs 
exhibit dynamic changes during metastatic progression. 
 
Metastatic growth is associated with hypovascularity 
 PDAC tumors are commonly hypovascular, leading to increased hypoxia as well 
as impaired drug delivery9,10. To characterize the vascular properties of metastatic 
lesions, we stained metastatic livers for VE-cadherin (VECAD) and calculated vessel 
density (VECAD+ lumen-containing blood vessels per 40x field). As expected given the 
high prevalence of vascular sinusoids in the normal liver, vessel density in the vicinity of 
small lesions (single cells and nano-metastases) was high, ranging between 25-30 
vessels per field (Fig. 2.11a,b). In bigger lesions, however, vessel density decreased, 
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approaching the mean of five vessels per field found in primary tumors (Fig. 2.11a,b). 
Quantification of the average distance from metastatic cells to the closest VECAD+ 
vessel produced a similar trend: single cells and nano-metastases were in close 
proximity to blood vessels (mean distance 5.4 ± 7.7 and 11.1 ± 9.2 microns, 
respectively) while cells within milli- and macro-metastases were far removed from the 
nearest blood vessel (mean distance 38.5 ± 30.1 and 36.2 ± 35.3 microns, respectively) 
similar to primary tumors (mean distance 19.2 ± 16.7 microns) (Fig. 2.11c). 
To assess whether these observations result in functional differences in 
perfusion, we injected tumor-bearing KPCY mice with Texas-red dextran, a high 
molecular weight fluorescent polysaccharide. Consistent with the observation that 
metastatic lesions become more hypovascular as they grow, we observed a “halo” of 
dextran-poor areas that became more prominent with increased size (Fig. 2.11d). These 
data demonstrate that metastatic PDAC liver lesions are initially well-vascularized and 
perfused but become progressively hypovascular with growth. To determine if this trend 
of decreasing vascularity with increasing lesion size holds true in human disease, we 
stained human PDAC tumors and matched small and large liver metastases for CD31 
and calculated vascular density as CD31+ vessels per micron. Consistent with our 
findings in the KPCY model, small but not large metastases had a higher vessel density 
compared to primary tumors (Fig. 2.11e,f). Thus, in both the KPCY model and human 
PDAC, metastatic growth is associated with decreasing vascular density. 
 
The impact of chemotherapy on metastasis 
 The studies described so far reveal that large metastatic lesions are 
hypovascular and surrounded by dense, desmoplastic stroma while small lesions and 
single cells, although well-perfused by nearby liver sinusoids, have not yet established a 
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local tumor microenvironment. As PDAC stroma has been proposed to act as a physical 
barrier to drug delivery in primary tumors9,10, we hypothesized that large metastases 
would be more resistant to chemotherapy compared to small lesions and single cells. To 
test the this “stromal barrier” hypothesis, we treated tumor-bearing KPCY mice with 
standard of care chemotherapy – the nucleoside analog gemcitabine (GEM) and the 
albumin-bound microtubule inhibitor nab-paclitaxel (PTX) – to examine the effects of 
chemotherapy on metastasis. Animals received intraperitoneal (IP) injections of GEM 
and PTX (each at 120 mg kg-1) every four days for 2-4 weeks, for a total of 4-8 doses of 
chemotherapy, and were sacrificed when moribund. Compared to untreated historical 
controls (matched for age and tumor weight; Fig. 2.12a,b), this treatment regimen led to 
a dramatic reduction in metastatic tumor burden with a decrease in the mean (± SD) 
number of lesions from 50.7 ± 64.9 (untreated) to 13.3 ± 13.0 (treated) (Fig. 2.13a). In 
addition, the metastases that did form were significantly smaller (Fig. 2.13b), with no 
macro-metastases and only a single milli-metastasis evident in chemotherapy-treated 
animals. Interestingly, chemotherapy also led to a reduction in the frequency of 
circulating tumor cells (CTCs) in tumor-bearing KPCY mice, with a log decrease in the 
mean number of CTCs from 141.6 ± 390.0 per ml (untreated) to 14.6 ± 14.6 per ml 
(treated) (Fig. 2.12c).  
We reasoned that GEM/PTX could shift the numerical and size distribution of 
metastases by either preventing the progression of small lesions or by reducing the 
burden of multicellular metastatic lesions at every stage. To distinguish between these 
possibilities, we treated tumor-bearing KPCY mice with a single dose of chemotherapy 
and assessed cell death in primary tumors and metastases 10-12 hours later by CC3 
staining. With the exception of single cells, metastases in all size categories exhibited a 
significant increase in CC3 staining after treatment (Fig. 2.13c, Fig. 2.12d). Surprisingly, 
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almost no cell death was observed in single YFP+ cells following GEM/PTX treatment 
(Fig. 2.13c), consistent with the observation that the number of single cell lesions did not 
change after chemotherapy (Fig. 2.13b). These data suggest that chemotherapy induces 
comparable degrees of cell death in lesions of all sizes greater than one cell.  
We considered the possibility that EMT is responsible for the apparent 
chemoresistance of single cells. EMT has been implicated in resistance to GEM in 
PDAC144-146, and since small metastases have high rates of EMT (Figure 2.4), we 
hypothesized that lesions treated with GEM/PTX for 2-4 weeks would be enriched for 
mesenchymal features. We assessed the expression of ECAD and FSP1 in untreated 
and treated primary tumors and small metastatic lesions, focusing only on single cells 
and nano-metastases since nearly all treated lesions fell into these two size categories 
(representative images in Fig. 2.14a,c). Surprisingly, treated primary tumors and 
metastatic lesions were significantly depleted of ECAD- and FSP1+ mesenchymal tumor 
cells (Fig. 2.14b,d). We then assessed the rate of apoptosis in ECAD+ and ECAD- tumor 
cells from mice treated with one dose of GEM/PTX and harvested 10-12 hours later. 
Consistent with the loss of mesenchymal tumor cells with long-term treatment, ECAD- 
tumor cells in the primary tumor and metastases had significantly higher rates of CC3 
positivity compared to ECAD+ cells (Fig. 2.14e,f). These data suggest that EMT 
promotes chemosensitivity in the context of GEM/PTX treatment. 
 
Discussion 
The highly inefficient nature of metastasis has made it difficult to observe the 
cellular and molecular events underlying tumor cell spread and growth at distant sites. 
As a result, most animal studies of metastasis have relied on transplantation of tumor 
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cell lines into recipient animals. In this study, we used a genetically engineered mouse 
model to characterize the key events that accompany metastatic growth, from single 
cells to large grossly detectable metastases. Importantly, the stochastic nature of tumor 
development and metastatic progression in the KPCY model allowed us to assess the 
natural history, and treatment response, of metastasis in the setting of naturally evolving 
and genetically heterogeneous tumors, an approach that has not been taken previously 
with any cancer type.  
The vast majority of animals with advanced pancreatic tumors had either overt or 
occult metastases, mirroring the human disease in which relapse is the norm despite 
surgery, with most lesions being smaller than 100 cells in size. Although small metastatic 
lesions exhibited features that distinguished them from primary tumors, they 
progressively acquired cell-intrinsic and –extrinsic features of the primary tumor. One of 
the biggest surprises of our study was that the rate of cell proliferation did not fluctuate 
with lesion size despite the dramatic changes in the microenvironment with progression. 
Large lesions were predominantly comprised of tumor cells with an epithelial phenotype, 
an observation consistent with the notion that epithelial properties are advantageous at 
metastatic sites39-41. Because proliferation rates did not vary across lesions and death 
rates were negligible, the tendency for large metastatic lesions to have an epithelial 
phenotype is most likely the result of MET rather than selective outgrowth of the 
epithelial population. Although the factors that drive EMT and MET in vivo remain to be 
determined, the observation that lesions acquire stroma as they grow represents one 
potential source of signals.  
Myofibroblasts appear early during metastatic growth, with most lesions having 
direct contact with myofibroblasts by the time they are 6-7 cells in size. This rapid 
recruitment suggests that factor(s) produced by the cancer cells either attract pre-
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existing myofibroblasts to the lesion or activate local stellate cells to differentiate into 
myofibroblasts. ECM deposition became more evident in advanced lesions, with macro-
metastases exhibiting levels of collagen I, fibronectin, hyaluronic acid and SPARC 
comparable to levels present in primary tumors, consistent with a recent study reporting 
similar levels of myofibroblasts, collagen, and hyaluronic acid in human primary 
pancreatic cancers and large metastases147.  
The vasculature also underwent dynamic changes during metastatic progression, 
with small lesions surrounded by blood vessels and larger lesions exhibiting 
hypovascularity, mirroring the hypovascular nature of primary PDACs in this model and 
in the majority of patients. Importantly, we found that human pancreatic tumors exhibit 
the same phenomenon, with small metastatic lesions having a higher vessel density 
than large lesions and primary tumors. Although the mechanism leading to vessel 
paucity in primary tumors and large metastases remains unknown, we recently showed 
that depletion of stromal fibroblasts (by interfering with Shh signaling) results in 
increased vessel density, suggesting that fibroblasts and/or ECM components exert an 
anti-angiogenic effect58. Hence, it is possible that hypovascularity is a consequence of 
increased myofibroblast activity. Regardless of the mechanism, it appears that the so-
called “angiogenic switch” – whereby tumor cells activate an angiogenic signal to 
increase their vascularity – is dispensable for the transition from micro-to macro-
metastasis in PDAC. 
For patients with metastatic PDAC, treatment with chemotherapy provides 
minimal improvement of survival22,23, whereas adjuvant chemotherapy for patients in 
clinical remission after initial resection offers a more substantial benefit, doubling overall 
survival. In the KPCY model, we observed killing in a wide spectrum of metastases, 
providing direct evidence that adjuvant chemotherapy targets lesions that are too small 
33 
 
to detect by standard imaging. We had initially hypothesized that small lesions, with their 
close proximity to endothelium and lack of stroma, would be particularly susceptible to 
chemotherapy, while large lesions, which are hypovascular and protected by stroma, 
would be resistant9-11. Thus, it was surprising that chemotherapy resulted in comparable 
levels of cell death in small lesions, large lesions, and primary tumors, while having only 
minimal impact on single cells. These results suggest that the stromal barrier hypothesis 
– which postulates that blood vessel paucity and desmoplastic stroma impedes the 
delivery of chemotherapy – is incomplete, at least with respect to metastatic lesions.  
There are several possible explanations for the apparent resistance of single 
cells to both long-term and short-term chemotherapy. The simplest possibility is that 
single disseminated cells are replenished by the primary tumor faster than they are 
being removed by chemotherapy. However, the observation that treated mice have 
significantly fewer CTCs would argue against this hypothesis. Mesenchymal tumor cells 
were acutely sensitive to chemotherapy, consistent with the observation by Collisson et 
al. that human and murine mesenchymal PDAC cell lines are more susceptible to 
gemcitabine compared to epithelial lines17. Single cells were enriched for epithelial 
features after long-term treatment, and since the average number of single cells did not 
differ between untreated and treated mice this likely reflects a mesenchymal-epithelial 
transition. Therefore, another possibility is that the epithelial plasticity of single 
disseminated cells plays a role in resistance to the combined treatment of gemcitabine 
and nab-paclitaxel. Finally, as nab-paclitaxel is thought to act by binding SPARC in the 
tumor microenvironment, increasing its local concentration, it is possible that the 
absence of SPARC near single cells spares them from cytotoxicity. This is an especially 
attractive mechanism in light of the fact that EMT induces SPARC expression148, and 
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there is significantly less EMT within treated lesions. While SPARC’s role in primary 
tumor chemosensitivity is disputed149-152, its role in metastasis is yet to be explored. 
Our data also have implications for the treatment of patients with resectable PDAC. 
KPCY animals treated for only 2-4 weeks with gemcitabine/nab-paclitaxel exhibited a 
marked improvement in metastatic burden, yet no animals had complete absence of 
metastatic disease. Indeed, this failure of combination chemotherapy to demonstrate 
“curative potential” in KPCY mice mirrors a critical failing of adjuvant chemotherapy for 
patients with PDAC; namely, improvement in median survival compared to observation, 
yet only rare long-term remissions or cures. Thus, even as gemcitabine/nab-paclitaxel 
and other combinations are beginning to be tested in the adjuvant clinical setting, our 
findings provide additional motivation to evaluate novel, non-chemotherapeutic 
approaches that target residual micrometastatic disease. 
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Materials and Methods 
Mouse Strains 
Pdx1-cre, KrasLSL-G12D, p53L/+, RosaYFP/YFP mice have been described previously124. 
KPCY mice were palpated and examined for evidence of morbidity twice per week. 
Tumor-bearing animals were sacrificed when moribund. Both male and female mice 
were used for analysis with a mean age of 22.6 ± 8.1 weeks. Pdx1-cre, RosaYFP/YFP mice 
were used as controls. All vertebrate animal experiments were conducted in compliance 
with the National Institutes of Health guidelines for animal research and approved by the 
University of Pennsylvania Institutional Animal Care and Use Committee. 
Immunofluorescence (IF) 
Tissues were fixed in Zn-formalin, paraffin embedded and stained as previously 
described 124. In brief, after sections were deparaffinized, rehydrated and subjected to 
antigen retrieval, sections were blocked in 5% donkey serum for 1 hour at room 
temperature (RT), incubated with primary antibodies for 1 hour at RT, washed, incubated 
with secondary antibodies for 1 hour at RT, washed and mounted. Rabbit anti-Zeb1 
(Santa Cruz Biotechnology, Santa Cruz, CA) required additional tyramide signaling 
amplification (PerkinElmer, Waltham, MA). See Table 2.3 for a list of antibodies used. 
Slides were visualized using an Olympus IX71 inverted multicolor fluorescent 
microscope. 
Metastasis Quantification 
Gross metastases were confirmed by fluorescent microscopy using a Leica MZ16FA 
multi-color fluorescent stereomicroscope. To determine metastatic burden, YFP+ lesions 
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were quantified for 5 liver sections spaced 100 µm apart. Large metastatic lesions that 
were captured on multiple sections were only counted once. 
Percent Area Quantification (IF) 
Percent area was determined for a subset of stains (αSMA, COL1, HA, SPARC, FN, 
CD45, F4/80, GR-1, CD3 & VECAD) by first cropping the image within one cell diameter 
of each metastatic lesion. Using ImageJ, fluorescent channels were split and the 
channel of interest was thresholded to highlight positive staining while excluding 
background. The ‘analyze particles’ tool was then used to calculate percent area. 
Fluorescent Dextran Administration 
Tumor-bearing mice were injected with 25 ug kg-1 Texas red-conjugated dextran (70,000 
MW; Thermofisher Scientific, Waltham, MA) 30 minutes prior to euthanasia. Tissues 
were embedded in OCT (Electron Microscopy Sciences, Hatfield, PA), cut into 5 um 
sections and imaged on an Olympus IX71 inverted multicolor fluorescent microscope. 
Human Specimens 
Tissue samples were obtained from patients who consented to a research autopsy in 
association with the IRB approved Johns Hopkins Rapid Medical Donation Program 
(PMID: 19273710). Clinicopathological characteristics are listed in Table 2.3. Formalin-
fixed and paraffin-embedded samples of the primary carcinoma, two independent gross 
liver metastasis sections from these patients were used for image analysis and 
immunohistochemistry. Micrometastases were detected within the normal liver 
parenchyma adjacent to gross liver metastases and were identified by nuclear atypia 
and larger cell size. 
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Immunohistochemistry 
Sections were deparaffinized in xylene, rehydrated and subjected to antigen retrieval. 
Endogenous peroxidases were blocked with 1.5% H2O2. Endogenous avidin and biotin 
were also blocked using an Avidin/Biotin Blocking Kit (Vector Labs, Burlingame, CA) 
according to the manufacturer’s instructions. Sections were then blocked with 5% 
donkey serum in 0.3% Triton-X100 (MP Biomedicals, Santa Ana, CA) in PBS for 1 hour 
at RT, then incubated with primary antibodies at 4oC overnight. The next day, slides 
were washed in 0.1% Tween-20 (Fisher Scientific, Pittsburgh, PA) in PBS (PBST) and 
incubated with a biotin-conjugated secondary antibody for 1 hour at RT. Slides were 
washed in PBST and staining was revealed using ABC-HRP and DAB kits (Vector Labs) 
according to the manufacturer’s instructions. 
Human CD31 quantification 
Immunolabeled slides were scanned at 200x total magnification at a resolution of 0.49 
µm/pixel using an Aperio Scanscope CS digital slide scanner (Aperio Technologies, Inc., 
Vista, CA). Aperio ImageScope was used to extract 735 µm2 (1500 x 1500 pixel) fields 
as TIFF images for further analysis. The fields were randomly selected in the area of 
interest using a low magnification view of the slide.  To compare vessel density in 
primary and metastatic tumor, up to five fields were extracted from each slide. The 
extracted fields were then analyzed with image analysis software written using ImageJ 
(Wayne Rasband, NIH, http://rsbweb.nih.gov/ij/). Total tissue area was measured by 
manually thresholding a grayscale version of the original field. The CD31-positive area 
was then measured by first masking out any areas with background staining using 
manual drawing tools and then performing color deconvolution to separate the DAB and 
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hematoxylin staining 153. The DAB image was then manually thresholded to select the 
CD31 positive pixels.  Particles (groups of connected pixels) less than 150 pixels (73.5 
µm2) in size were excluded to reduce the degree of large vessel fragmentation and the 
presence of single immunoreactive cells. CD31+ vessel density was calculated as the 
number of CD31 positive particles/total tissue area.  
Chemotherapy Administration 
Tumor-bearing animals in healthy condition were enrolled once the tumor had reached 
an estimated 1 cm in diameter based on palpation. With the knowledge that the average 
number of metastases per mouse in our historical, untreated controls is 50.7 (± 64.9), we 
concluded that a large effect size of at least a 75% decrease in metastasis with a 
relatively small (≤10) standard deviation would be necessary to detect significant 
changes after treatment. Using these values, with an alpha error level of ≤5%, we 
determined that a sample size of 8 mice would be sufficient. Gemcitabine-HCl (Sun 
Pharmaceuticals, Mumbai, India) and nab-paclitaxel (Abraxane; Celgene, Summit, NJ) 
were both dissolved in PBS and administered via intraperitoneal injection at 120 mg kg-1. 
The drugs were administered simultaneously once every four days until the mouse 
became moribund, between 2-4 weeks from enrollment. Each mouse received at least 4 
(and a maximum of 8) doses. 
Flow Cytometry 
Blood was collected by cardiac puncture as previously described 124. Erythrocytes were 
removed using RBC lysis buffer (G-biosciences, St. Louis, MO) according to the 
manufacturer’s instructions. The remaining cellular fraction was stained with APC anti-
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mouse CD45 (Biolegend, San Diego, CA) and analyzed on a BD FACSVerse flow 
cytometer. DAPI-/ CD45-/YFP+ events were counted as circulating tumor cells. 
Statistical Analysis 
Differences between two groups were analyzed by two-tailed Student’s t-test with 
Welch’s correction to account for unequal SDs, or by Mann-Whitney test for non-
normally distributed data. Differences between three or more groups were analyzed by 
one-way ANOVA with Tukey’s multiple comparisons test used as a post hoc test to 
assess differences between ‘single cells’ and all other groups. For experiments in which 
‘single cell’ means were binary (0 or 100%), differences between ‘single cells’ and all 
other groups were analyzed by one-sample t-test. All statistical analyses were performed 
using GraphPad Prism 6 (GraphPad, La Jolla, CA). P ≤ 0.05 denotes differences that 
are statistically significant. 
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Chapter 2 Figures and Figure Legends 
 
 
Figure 2.1: Metastatic landscape of the KPCY model. (a) Representative images of 
YFP+ liver metastases and primary tumor. Scale bars, 50μm. (b) Size distribution of 
metastatic lesions in the liver grouped according to size (n=23 mice). (c) Quantification 
of KI67+ (p=0.9439) tumor cells in liver metastases (n= 6 mice, 159 lesions). (d) 
Quantification of CC3+ (p= 0.1621) tumor cells in liver metastases (n= 4 mice, 46 
lesions). P-values were calculated by one-sample t-test against ‘single cell’ means. Data 
are presented as mean ± SD. 
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Figure 2.2: Proliferation/apoptosis rates of metastatic lesions. (a) Proliferation. 
Primary tumor and metastases were stained for YFP (red), DAPI (blue) and Ki67 
(green). (b) Mitosis. Primary tumor and metastases were stained for YFP (red), DAPI 
(blue) and pH3 (green). (c) PCNA expression. Primary tumor and metastases were 
stained for YFP (red), DAPI (blue) and PCNA (green). (d) Apoptosis. Primary tumor and 
metastases were stained for YFP (red), DAPI (blue) and CC3 (green). (e) Quantification 
of pH3 staining; p= 0.9633. (f) Quantification of PCNA staining; p=0.0642. Bars 
represent means ± SD. Scale bars, 50 μm. 
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Figure 2.3: Proliferation in human PDAC tumors and metastases. (a-c) 
Representative images of a micrometastatic lesion (a), gross metastasis (b) and primary 
tumor (c) stained for Ki67 by IHC. (d) Quantification of Ki67 staining. The percentage of 
Ki67+ cells was determined for micro-metastases (n=126), gross metastases (n=11) and 
primary tumors (n=7); p=0.3890. For large lesions (gross metastases and primary 
tumors), five fields were averaged together. Bars represent means ± SD.  
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Figure 2.4: Metastatic growth is associated with a more epithelial phenotype. (a-d) 
Representative images of metastases and primary tumor stained for DAPI (blue), YFP 
(red) and ECAD (a), CLDN7 (b), FSP1 (c) and ZEB1 (d) (green). Scale bars, 50 μm. (e) 
Quantification of EMT in metastases. The percent of positive cells for each lesion was 
determined and the percentages were averaged across lesions of the same size (ECAD, 
p<0.05; CLDN7, ns; FSP1, p<0.05; ZEB1, ns). n ≥ 8 mice, ≥100 lesions for each stain. 
Data are presented as mean ± SD. P values were calculated by one-way ANOVA and 
one sample t-tests against ‘single cell’ means; *, p<0.05. 
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Figure 2.5: Skewing of epithelial to mesenchymal cell ratio within primary tumor 
and metastatic lesions. (a-f) Comparison of epithelial (ECAD+, CLDN7+) and 
mesenchymal (FSP1+, ZEB1+) cell frequency within each size category. Bars represent 
means ± SD; *, p<0.05; **, p<0.01; #, p<0.001; ##, p<0.0001. 
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Figure 2.6: Epithelial and mesenchymal features of human PDAC tumors and 
metastases. (a-c) Representative images of human microscopic liver metastasis 
(n=114), gross liver metastasis (n=24) and primary PDAC tumors (n=6) stained for 
CLDN7 by IHC. (d) Quantification of CLDN7+ area per 20X field for gross metastases 
and primary tumors or within one cell diameter for micro-metastases. (e-g) 
Representative images of human microscopic liver metastasis (e), gross liver metastasis 
(f) and primary PDAC tumors (g) stained for FSP1 by IHC. (h) Quantification of FSP1+ 
area per 20X field for gross metastases (n=18) and primary tumors (n=6) or within one 
cell diameter for micro-metastases (n=57). For large lesions (gross metastases and 
primary tumors), five fields were averaged together. Bars represent means ± SD; *, 
p<0.05; **, p<0.01; #, p<0.001; ##, p<0.0001.  
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Figure 2.7: Desmoplasia accumulates as lesions grow. (a) Representative images of 
metastases and primary tumor stained for DAPI (blue), YFP (red) and ɑ-SMA (green). 
Scale bars, 50μm. (b) Contact between metastases and ɑ-SMA+ fibroblasts. Each lesion 
was binned by size and scored for direct contact with an ɑ-SMA+ cell (n= 9 mice, 167 
lesions). (c) ɑ-SMA+ fibroblast density at metastatic lesions. Percent ɑ-SMA+ area was 
quantified within one cell diameter of metastatic lesions (n= 9 mice, 167 lesions). (d-g) 
Extracellular matrix (ECM) density at metastatic lesions. Metastatic livers were stained 
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for ECM components COL1 (d), HABP (e), SPARC (f) and FN (g). Percent positive area 
was quantified within one cell diameter of each lesion. n ≥ 5 mice, ≥ 50 lesions for each 
stain. Data are presented as mean ± SD. P values were calculated by one-way ANOVA 
and one sample t-tests against ‘single cell’ means; *, p<0.05; **, p<0.01; #, p<0.001; ##, 
p<0.0001. 
  
48 
 
 
Figure 2.8: Myofibroblast contact with nano-metastases depends on cell size and 
representative images of ECM stains. (a) Contact between nano-metastases and 
myofibroblasts by cell number. Data are shown as mean ± SD. P values were calculated 
by one sample t-tests against ‘single cell’ mean; *, p<0.05. (b-e) Representative images 
of primary tumor and metastases stained for YFP (red), DAPI (blue) and (b) Collagen 1 
(COL1); (c) Hyaluronic acid binding protein (HABP); (d) Secreted protein acidic and rich 
in cysteine (SPARC); and (e) Fibronectin (FN) in green. Scale bars, 50μm. 
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Figure 2.9: Fibronectin deposition in human PDAC tumors and metastases. (a-c) 
Representative images of human microscopic liver metastasis (n=52), gross liver 
metastasis (n=18) and primary PDAC tumors (n=6) stained for FN by IHC. (d) 
Quantification of FN+ area per 20X field for gross metastases and primary tumors or 
within one cell diameter for micro-metastases. For large lesions (gross metastases and 
primary tumors), five fields were averaged together. Bars represent means ± SD; *, 
p<0.05. 
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Figure 2.10: Leukocytes accumulate in metastatic livers. (a-d) Representative 
images of CD45 (a), F4/80 (b), Gr-1 (c) and CD3 (d) staining (green) and DAPI (blue) in 
uninvolved areas of control (Pdx1-cre, RosaY/Y) and metastatic (KPCY) livers. Scale 
bars, 50μm. (e) Quantification of leukocyte density in uninvolved areas of liver (CD45, 
p=0.0002; F4/80, p<0.0001; Gr-1, p<0.0001; CD3, p=0.3243). (f-j) Representative 
51 
 
images of leukocyte density at metastatic lesions. Metastases and primary tumor were 
stained for YFP (red), DAPI (blue) and (f), CD45 (leukocytes); (g), F4/80 (macrophages); 
(h), Gr-1 (MDSCs); and (j), CD3 (T cells) in green. Scale bars, 50μm. (k-n) Quantification 
of leukocyte density at metastatic lesions. The percent positive area for each leukocyte 
stain was quantified within one cell diameter of metastatic lesions. Data are presented 
as mean ± SD. Data are presented as mean of the percent positive area within a 40X 
field ± SD. n ≥ 5 mice, ≥ 50 lesions for each stain. P values were calculated by one-way 
ANOVA and unpaired Student’s t-test with Welch’s correction; *, p<0.05; **, p<0.01; #, 
p<0.001; ##, p<0.0001. 
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Figure 2.11: Metastatic growth is associated with functional hypovascularity. (a) 
Representative images of metastases and primary tumor stained for VECAD (green), 
YFP (red) and DAPI (blue). Scale bars, 50μm. (b) Metastatic vessel density. VECAD+ 
blood vessels were quantified at metastases within 40x fields. Data are presented as 
mean ± SD; n = 7 mice, 100 lesions. (c) Proximity to blood vessels. For each lesion, the 
distance between five random tumor cells and the nearest VECAD+ blood vessel was 
determined. Data are presented as mean ± SD. n = 7 mice, 100 lesions. P values were 
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calculated by one-way ANOVA and one sample t-tests against ‘single cell’ means. (d) 
Functional hypovascularity at large metastases. Representative images of fluorescent 
dextran accumulation (red) at metastatic lesions (YFP, green; DAPI, blue). (e) 
Representative images of human primary PDAC and matched liver metastases stained 
for CD31 (brown). Scale bars, 50μm. (f) Mean vessel density quantification of human 
primary PDAC and matched liver metastases (n=25 cases). Data are presented as mean 
± SD; *, p<0.05; **, p<0.01; #, p<0.001; ##, p<0.0001. 
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Figure 2.12: Circulating tumor cells (CTCs) are decreased after long-term 
chemotherapy. (a-b) Age at death (a) and tumor weight (b) for untreated historical 
controls and treated animals. Lines represent mean ± SD. P value by Student’s t-test. (c) 
CTCs in untreated (n=23) and treated (n=8) mice; *, p < 0.05. Lines represent the mean. 
P value by Student’s t-test. (d) Representative images of untreated and treated 
metastatic lesions stained for CC3 (green), YFP (red) and DAPI (blue). Scale bars, 
50μm. 
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Figure 2.13: Chemotherapy reduces metastatic burden. (a) Liver metastatic burden 
after long-term chemotherapy. Each dot represents one mouse. Untreated group 
consists of historical controls from Figure 1B (untreated, n= 23; treated, n=8). Bars 
represent means ± SD; *, p<0.05, Student’s t-test with Welch’s correction. (b) Size 
distribution of metastatic lesions after long-term chemotherapy. Data are presented as 
mean ± SD, *, p<0.05, Student’s t-test with Welch’s correction. (c) Apoptosis rates in 
metastases after single dose chemotherapy. CC3 positivity in metastases was assessed 
10-12 hours after treatment. Each dot represents a lesion; line represents the mean. *, 
p<0.05; **, p<0.01; #, p<0.001 by Mann-Whitney test. 
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Figure 2.14 Mesenchymal tumor cells are depleted after chemotherapy. (a) 
Representative images of untreated and treated (GEM/PTX for 2-4 weeks) primary 
tumors and small metastatic lesions stained for ECAD (green), YFP (red) and DAPI 
(blue). (b) Quantification of ECAD- tumor cells in untreated and treated primary tumors 
and small metastatic lesions. (c) Representative images of untreated and treated 
primary tumors and small metastatic lesions for FSP1 (green), YFP (red) and DAPI 
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(blue). (d) Quantification of FSP1+ tumor cells in untreated and treated primary tumors 
and small metastatic lesions. n ≥ 7 mice for each condition. Bars represent means ± SD. 
Statistical significance was determined by Student’s t-test with Welch’s correction. (e) 
Representative images of treated (1 dose GEM/PTX) primary tumor and liver metastasis 
stained for CC3 (green), ECAD (cyan), YFP (red) and DAPI (blue). Arrows denote 
YFP+/ECAD+/CC3+ cells, arrowheads denote YFP+/ECAD-/CC3+ cells. (f) Quantification 
of CC3 staining in ECAD+ and ECAD- tumor cells (n ≥ 4 mice). Bars represent means ± 
SD. Statistical significance was determined by Mann-Whitney test. Scale bars, 50 um. *, 
p<0.05; **, p<0.01; #, p< 0.001; ##, p < 0.0001.  
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Chapter 2 Tables 
 
 
Table 2.1: Metastatic burden (raw counts) for each animal used in Figure 3b. 
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Table 2.2: Antibodies used in Chapter 2.
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Table 2.3: Clinicopathological characteristics of patients. Abbreviations: standard 
deviation (SD); overall survival (OS); month (mo); number of patients (n); wildtype (WT). 
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CHAPTER 3: A non-canonical mechanism drives 
epithelial plasticity in vivo 
 
Abstract 
 Metastasis is responsible for the majority of cancer-related deaths, and yet the 
molecular mechanisms underlying tumor cell spread remain elusive. It is widely believed 
that epithelial-to-mesenchymal transition (EMT) – during which epithelial cells lose their 
adhesive behavior and acquire a fibroblast-like morphology and migratory behavior – is 
an important step in cancer progression154. EMT is reawakened during tumorigenesis in 
mouse models124,155,156, where it contributes to invasion and hematogenous 
dissemination81,82,157. EMT is thought to be regulated primarily at the transcriptional level 
through the repressive activity of EMT transcription factors (EMT-TFs) on epithelial 
genes including E-cadherin (Cdh1)158,159. However, these canonical EMT mechanisms 
have been parsed out almost exclusively in vitro under defined experimental conditions, 
and the molecular programs that drive EMT in physiological context remain to be 
delineated. Here, we describe a post-translational mechanism that accounts for EMT in 
the majority of tumors in a murine model of pancreatic ductal adenocarcinoma (PDAC). 
This “non-canonical” program employs epithelial protein internalization, rather than 
transcriptional repression, to suppress the epithelial program. At a global transcriptional 
level, tumors utilizing this alternative EMT program are associated with the recently 
identified classical/progenitor/exocrine transcriptional subtypes of PDA, while those 
tumors utilizing canonical EMT programs correspond to the squamous/basal/quasi-
mesenchymal subtype of PDAC. Most strikingly, tumor cells utilizing non-canonical EMT 
mechanisms exhibit greater epithelial-mesenchymal plasticity and tumor initiation 
capacity compared to tumor cells utilizing canonical mechanisms. Taken together our 
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data demonstrate that the programs driving tumor-associated EMT in vivo differ 
dramatically from the classically described Tgfβ-Snail-Twist axis. 
Introduction 
Metastasis is responsible for the majority of cancer-related deaths, and yet the 
molecular mechanisms underlying tumor cell spread remain elusive. During a tumor 
cell’s journey to the metastatic site it must adapt to ever-changing obstacles, from local 
desmoplasia to the circulatory system to foreign and potentially hostile 
microenvironments. Thus a key feature of any successful metastasizing cell is plasticity. 
It is widely believed that epithelial-mesenchymal transition (EMT) and the reverse 
process mesenchymal-epithelial transition (MET) are responsible for ushering cancer 
cells through the gauntlet of the metastatic cascade154. During EMT, an epithelial cell 
loses its apicobasal polarity and adhesion to neighboring cells to take on a more 
fibroblast-like morphology and migratory behavior86. EMT is an evolutionarily conserved 
program critical for aspects of embryogenesis that require dynamic cellular movements, 
such as gastrulation and neural crest cell migration38,160. We and others have 
demonstrated that EMT is reawakened during spontaneous tumorigenesis in mouse 
models156,161,162, in some cases even before frank malignancy124,163. EMT appears to be 
vital for early steps of metastasis (hematogenous dissemination)39-41, however metastatic 
lesions tend to have an epithelial histology35,132,156 and numerous studies have 
demonstrated that reversion back to an epithelial state is essential for later steps of 
metastasis (colonization)39,40. 
 Canonical mechanisms of EMT hinge on the transcriptional repression of 
epithelial genes, most notably E-cadherin, by various EMT transcription factors such as 
Snail, Slug, Twist and Zeb1/286. These transcription factors are induced by many 
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different extracellular signals, including but not limited to TGFβ164, HGF165, WNT166 and 
EGF167, and are negatively regulated by microRNAs such as mir-3493,94 and the miR-200 
family97,99,168. To date, the mechanisms driving EMT have been parsed out almost 
exclusively in vitro under pre-defined conditions (ie, by using recombinant TGFβ or 
overexpressing Snail), but it remains to be seen whether the machinery that regulates in 
vitro EMT is physiologically relevant. Here we show that in vivo, and in contrast to 
canonical mechanisms, EMT is driven primarily by post-translational regulation of the 
epithelial program which we have termed non-canonical EMT. This alternative 
mechanism has functional consequences for tumor cells, as it promotes greater 
epithelial-mesenchymal plasticity and enhances tumor initiation and metastasis 
compared to canonical EMT. 
 
Results and Discussion 
EMT is accompanied by dramatic morphological and molecular changes during 
which epithelial markers are lost while mesenchymal markers, including transcription 
factors and cytoskeletal components, are gained. The loss of E-cadherin (Ecad) is 
considered a hallmark of EMT, and we found that in the pancreatic tumors of Pdx1-cre; 
LSL-KrasG12D; P53loxP/+; LSL-RosaYFP/YFP (KPCY) mice, 89% ± 11.9 (mean ± SD) of YFP+ 
tumor cells that had delaminated from epithelial structures were negative for 
membranous Ecad (Fig. 3.1a). By contrast, only a fraction of tumor cells that had lost 
Ecad staining also exhibited higher expression of mesenchymal markers or EMT-TFs 
such as zinc-finger E-box homeobox 1 (Zeb1), slug (Snai2), vimentin (Vim), or fibroblast-
specific protein 1 (Fsp1) (Fig. 3.2a-e). Moreover, expression of these mesenchymal 
markers was rarely observed in tumor cells that were positive for membranous Ecad. 
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Thus, Ecad loss, rather than the gain of a single mesenchymal marker, is the most 
reliable indicator of cells that have undergone EMT in this model. 
 To better understand the transcriptional changes associated with EMT in vivo, we 
used fluorescence-activated cell sorting (FACS) to isolate Ecad+ (epithelial; E) and Ecad- 
(mesenchymal; M) YFP+ cancer cells from 11 primary KPCY tumors for RNA sequencing 
(Fig. 3.1a-b; Fig. 3.3a). We confirmed accurate sorting by visual inspection of sorted 
cells and ruled out contamination of non-tumor cells by performing qPCR for Cd45 and 
YFP (Fig. 3.3b-d). Although we expected Ecad+ samples to be closely related to each 
other and distinct from the Ecad- samples, principal component analysis and 
unsupervised hierarchical clustering arranged samples into two subgroups organized 
independently of epithelial-mesenchymal status but instead according to tumor identity 
(Fig. 3.1c,d). In the first tumor subgroup (3/11), EMT was associated with robust 
downregulation of Ecad mRNA (Fig. 3.1e,f), as expected. In the second subgroup (8/11), 
by contrast, EMT was associated with stable levels of mRNA for Ecad and other 
epithelial genes (Fig. 3.1e,f). Thus, loss of the epithelial program occurs in the absence 
of transcriptional repression in the majority of KPCY tumors undergoing EMT. 
To distinguish between these mechanisms, we applied the term canonical EMT 
(C-EMT) to refer to those tumors in which the epithelial program was eliminated by 
transcriptional repression and the term non-canonical EMT (NC-EMT) to refer to those 
tumors in which the epithelial program was suppressed by other means. Tumors in both 
subgroups exhibited a robust upregulation of mesenchymal-related transcripts within the 
Ecad- population, including periostin (Postn), fibroblast-activated protein (Fap), platelet 
derived growth factor receptor beta (Pdgfrβ), GLI-Kruppel family member 1 (Gli1), 
tenascin C (Tnc), secreted protein acidic and cysteine rich (Sparc), podoplanin (Pdpn), 
palladin (Palld) and numerous collagens (Fig. 3.1f). Gene set enrichment analysis 
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(GSEA) of both C- and NC-EMT samples confirmed that Ecad- transcriptomes strongly 
correlated with published EMT datasets (Fig. 3.4). Importantly, transcripts for several 
known EMT-TFs – Snai2, Twist1, Zeb1 and ETS variant 1 (Etv1) – were significantly 
more abundant in C-EMT tumors (Fig. 3.5), possibly accounting for the marked reduction 
in epithelial transcripts in Ecad- samples from these tumors. Thus, tumors characterized 
as either C-EMT or NC-EMT exhibit overlapping EMT-associated mesenchymal 
programs despite having distinct mechanisms for repressing their epithelial programs 
during EMT. 
 We noticed that tumors categorized as C-EMT tended to be poorly differentiated 
while tumors characterized as NC-EMT tended to be moderately-to-well differentiated 
(Fig. 3.6). Consequently, we hypothesized that these two modes of EMT may be related 
to known PDAC subtypes, which also exhibit histological heterogeneity. To test this, we 
compared our KPCY tumor transcriptomes to three reported PDAC subtype signatures 
(Fig. 3.7). In all cases, C-EMT tumors were strongly associated with poorly-differentiated 
subtypes (quasi-mesenchymal, squamous, and basal-like) while NC-EMT tumors were 
strongly associated with well-differentiated subtypes (classical/exocrine-like, pancreatic 
progenitor/ADEX, and classical)17-19. Hence, the mode by which the epithelial phenotype 
is lost in murine models of PDAC correlates with transcriptional subtypes in human 
PDAC, suggesting that tumor class dictates EMT mechanism in vivo.  
 To further understand these distinct mechanisms, we developed a quantitative 
PCR (qPCR) signature that could distinguish between C- and NC-EMT and applied it to 
a panel of mouse and human PDAC cell lines (Fig. 3.8a,b). As predicted, cell lines 
expressing the C-EMT signature exhibited robust down-regulation of Ecad mRNA when 
FACS sorted into Ecad+ and Ecad- populations. By contrast, cell lines expressing the 
NC-EMT signature exhibited no change in Ecad mRNA levels when Ecad+ and Ecad- 
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cells were compared (Fig. 3.8c,d). This suggests that canonical and non-canonical 
mechanisms of Ecad repression are retained in cell lines derived from mouse and 
human PDAC. Using principal component analysis, we also found a significant 
correlation between the C-EMT and quasi-mesenchymal PDAC subtypes, and the NC-
EMT and classical PDAC subtypes in human PDAC cell lines, consistent with our 
findings in murine PDAC tumors and cell lines (Fig. 3.8e). The relationship between 
tumor subtypes and mode of EMT also applies to breast cancer. Luminal A/B and 
normal-like breast cancer cell lines, which tend to be well differentiated, are strongly 
associated with a non-canonical EMT transcriptional profile, while poorly differentiated 
basal cell lines tend to have a canonical EMT expression pattern (Fig. 3.8f).   
EMT is often induced in vitro by treating cells with specific growth factors, most 
commonly Tgfβ. As expected, our PDAC cell lines exhibited morphological features of 
EMT (Fig. 3.9a) with loss of Ecad protein (Fig. 3.9b) upon Tgfβ treatment. Exposure to 
Tgfβ resulted in robust transcriptional down-regulation of Ecad and up-regulation of 
Snail, Slug and Zeb1, regardless of whether the cell line was categorized as C-EMT or 
NC-EMT (Fig. 3.9c). This suggests that cell lines that utilize non-canonical EMT 
mechanisms under standard culture conditions remain competent to employ a canonical 
mechanism when confronted with an exogenous (and overriding) growth factor signal. 
 We next sought to understand the NC-EMT phenotype using our stratified murine 
PDAC cell lines. Since Ecad mRNA abundance remained unchanged during NC-EMT, 
we examined the fate of Ecad protein during this process. First, to determine whether 
residual Ecad mRNA was being translated, we sorted cells from our cell line panel into 
Ecad+ (E) and Ecad- (M) fractions and compared Ecad protein levels in whole cell 
lysates (Fig. 3.10a). While the M fraction from C-EMT cell lines lacked any Ecad protein, 
as expected, the M fraction from NC-EMT cell lines retained Ecad protein (Fig. 3.10b). 
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Other epithelial proteins, including claudin-7 (Cldn7) and epithelial cell adhesion 
molecule (Epcam) were also maintained upon NC-EMT at the transcript and protein 
levels (Fig. 3.10b). In contrast, C-EMT cell lines did not express appreciable levels of 
these proteins in either the E or M fraction.  Levels of p120-catenin, an important direct 
Ecad regulator, did not vary between E and M in either C- or NC-EMT cell lines. 
However, NC-EMT cell lines expressed both 1A (mesenchymal) and 3A (epithelial) 
isoforms169 while C-EMT cell lines only expressed the 1A isoform (Fig. 3.10b). These 
data demonstrate that epithelial proteins continue to be translated in cells that have 
undergone NC-EMT.  
 We reasoned that Ecad internalization might account for the lack of membrane 
staining in NC-EMT. To test this, we performed dual antibody live cell 
immunofluorescence by first staining live cells for Ecad using the fluorophore BV421 (to 
detect membrane-associated Ecad; M-Ecad) followed by fixation, permeabilization and a 
second staining of Ecad using the fluorophore APC (to detect intracellular Ecad; I-Ecad) 
(Fig. 3.10c). As expected, C-EMT cells lacking membranous Ecad (M-Ecad-) were 
negative for I-Ecad, consistent with the loss of Ecad mRNA (Fig. 3.10d). In NC-EMT cell 
lines, by contrast, the majority of M-Ecad- cells were positive for I-Ecad (Fig. 3.10d). 
Consistent with this finding, we detected I-Ecad in sections from tumors expressing a 
NC-EMT signature (Fig. 3.10e) but not those expressing a C-EMT signature (Fig. 3.10f). 
These results suggest that Ecad protein is internalized by cells undergoing NC-EMT 
both in vitro and in vivo.  
 We next investigated the molecular mechanisms responsible for changes in Ecad 
localization and abundance. The only known EMT-related transcription factor 
significantly upregulated in mesenchymal NC tumor samples compared to epithelial NC 
tumor samples was pair-related homeobox 1 (Prrx1) (Fig. 3.11a). Prrx1 acts as a 
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transcriptional activator and has been described as “a more potent mesenchymal 
inducer than epithelial repressor”86, fitting the profile of a potential NC-EMT regulator. 
Prrx1 produces two isoforms, Prrx1a and Prrx1b, which are associated with epithelial 
and mesenchymal phenotypes, respectively170,171. Surprisingly, we did not observe 
isoform switching from Prrx1a to Prrx1b between NC-E and –M tumor samples; rather 
both isoforms were significantly increased in NC-EMT. Hence we sought to determine 
whether overexpression of one or both Prrx1 isoforms was sufficient to drive the NC-
EMT phenotype, specifically Ecad internalization. Using the PiggyBAC transposon 
system, we overexpressed Prrx1a, Prrx1b, both isoforms simultaneously or the control 
vector in C- and NC-EMT KPCY cell lines and assessed their effects on Ecad surface 
expression and internalization. Overexpression of the mesenchymal isoform, Prrx1b, 
resulted in a subtle but significant increase in M-ECAD- NC-EMT cells compared to the 
control while Prrx1a alone and Prrx1a/b dual expression had no effect on the frequency 
of M-ECAD- cells (Fig. 3.11b). Interestingly, the frequency of M-ECAD-/I-ECAD+ cells 
was significantly increased in an NC-EMT cell line with overexpression of any 
combination of Prrx1 isoforms compared to control, suggesting that both Prrx1 isoforms 
promote the retention of Ecad in the cytoplasm (Fig. 3.11c). These data suggest that 
while Prrx1 may not be a master regulator of the NC-EMT program, it does play a role in 
the post-translational regulation of Ecad, which is a prominent feature of the NC-EMT 
phenotype. 
 Finally, we explored the functional impact of C- and NC-EMT with respect to 
tumor initiation and epithelial plasticity. We used flow cytometry to sort cell lines into 
Ecad+ (E) and Ecad- (M) populations and then assessed subcutaneous tumor initiation 
potential by in vivo limiting dilution. While the tumor-initiating cell (TIC) frequency was 
the same for canonical Ecad+ (C-E), canonical Ecad- (C-M) and non-canonical Ecad+ 
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(NC-E) cells, non-canonical Ecad- (NC-M) cells exhibited a significantly higher rate of 
tumor outgrowth (Fig. 3.12a,b). Hence, non-canonical EMT is associated with a higher 
capacity to initiate tumors. We harvested the resulting tumors from the limiting dilution 
assay to assess epithelial plasticity. NC-E and –M tumors had high Ecad expression 
similar to unsorted NC tumors, and C-E and –M tumors had low Ecad expression 
resembling unsorted C tumors (Fig. 3.12c). These data suggest that NC-M cells and C-E 
cells are highly plastic, since they exhibit the largest shift in Ecad positivity. In both EMT 
subtypes, sorted tumors skewed in the same direction as unsorted tumors (NC toward 
epithelial, C toward mesenchymal), suggesting that the cells exhibit memory of the 
original epithelial:mesenchymal ratio, or reach an equilibrium determined by as yet 
unknown factors.  
 In summary, we have shown that pancreatic cancer cells employ two distinct 
mechanisms for shedding their epithelial programs during EMT in vivo – one utilizing 
transcriptional repression of epithelial genes and another involving post-translational 
regulation of protein localization and stability. Given prior work showing that Ecad is 
subject to dramatic trafficking and turnover in normal epithelial cells172-175, it is not difficult 
to envision how cancer cells might utilize such post-translational mechanisms to lose 
their epithelial properties. Moreover, cytoplasmic Ecad staining has previously been 
observed in surgical PDAC specimens, suggesting the process is conserved in human 
PDAC176. Protein relocalization could also help explain the phenomenon of circulating 
tumor cell clusters177-179, as the greater plasticity afforded by NC-EMT might permit 
tumor cells to become invasive while still retaining their adhesive properties. Although 
EMT has customarily been viewed as a transcriptionally regulated process, our 
identification of an alternate mechanism for suppressing the epithelial program – one 
70 
 
that underlies EMT in the majority of PDAC tumors in vivo – underscores the importance 
of examining the process under physiological conditions.  
Materials and Methods 
Mouse Strains 
Pdx1-cre, KrasLSL-G12D, p53L/+, RosaYFP/YFP mice have been described previously124. 
KPCY mice were palpated and examined for evidence of morbidity twice per week. 
Tumor-bearing animals were sacrificed when moribund. Both male and female mice 
were used for analysis with a mean (±SD) age of 16.3 (± 8.5) weeks. All vertebrate 
animal experiments were conducted in compliance with the National Institutes of Health 
guidelines for animal research and approved by the University of Pennsylvania 
Institutional Animal Care and Use Committee. 
Immunofluorescence (IF) 
Tissues were fixed in Zn-formalin, paraffin embedded and stained as previously 
described124. In brief, after sections were deparaffinized, rehydrated and subjected to 
antigen retrieval, sections were blocked in 5% donkey serum for 1 hour at room 
temperature (RT), incubated with primary antibodies for 1 hour at RT, washed, incubated 
with secondary antibodies for 1 hour at RT, washed and mounted. Rabbit anti-Zeb1 
(Santa Cruz Biotechnology, Santa Cruz, CA) required additional tyramide signaling 
amplification (PerkinElmer, Waltham, MA). See Table 3.1 for a list of antibodies used in 
Chapter 3. Slides were visualized using an Olympus IX71 inverted multicolor fluorescent 
microscope or a Zeiss LSM 710 confocal microscope. Confocal images were taken with 
Zen 2011 software and spectral imaging coupled with image analysis using linear 
unmixing was performed when necessary. 
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Fluorescence activated cell sorting (FACS) and flow cytometry 
FACS was used to sort KPCY cell lines as well as primary KPCY pancreatic tumors. To 
prepare cell lines, cells were incubated in cell dissociation buffer (Thermofisher) at 37oC 
for 15-60 minutes. To prepare tumors and create a single cell suspension, pancreatic 
tissue was rinsed vigorously in cold DMEM/F12 three times before mincing with scissors 
(approximately 100 chops). The minced pieces were then incubated in preheated 
collagenase with protease inhibitors (2 mg/ml; Sigma) for 20 min at 37°C. Vigorous 
vortexing was performed every 5 min during this incubation. The dissolved pieces were 
then poured over a 40 μM cell strainer and the large remaining pieces of tissue were 
mechanically dissociated using the plunger of a 3mL syringe. The flow through was 
resuspended in cold 2% FCS/DMEM/F12, centrifuged, washed once, and kept on ice in 
the dark. Samples were incubated with the primary antibody (1:200) and then secondary 
antibody (1:100) in 10% FCS /DMEM/F12 for 15 min at 4°C. Dissociated cells were 
stained for E-cadherin (ECCD-2 clone, Thermofisher) prior to sorting on either the 
FACSVantage or Influx (BD) and flow cytometry on the LSRII (BD). Sorting and flow 
cytometry were performed at the Penn PathBioResource Flow Cytometry Core. 
RNA isolation, library construction, and next-generation sequencing 
RNASeq libraries were prepared using the Clontech Ultra low RNA kit – HV, with 12 
cycles of PCR for cDNA amplification, and the Clontech Low Input Kit for library prep, 
with 9 cycles of PCR amplification, following the manufacturer’s protocol. The amplified 
library was purified using AMPure beads, quantified by Qubit and QPCR, and visualized 
in an Agilent Bioanalyzer. The libraries were pooled equimolarly, and loaded on either 
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one rapid run HiSeq 2500 flow cell, onboard clustering protocol, or on HiSeq 25000 high 
output flow cell lanes, as paired 50 nucleotide reads. 
Sequencing alignment, differential gene expression and clustering analysis 
The quality of raw reads was assessed using Fastqc (v0.11). Reads passing quality 
control were aligned to the mouse genome version NCBI GRCm38/mm10 with STAR 
(v2.3.1) using default parameters. Total reads, with alignment quality of at least 10, 
mapping to each gene were counted using HTseq-count and GRCm38/mm10 gene 
annotation files. Differential gene expression analysis was performed using the 
R/Bioconductor package DESeq2. Genes with Benjamini-Hochberg adjusted P values ≤ 
0.1 and absolute log2 fold change ≥ 1.0 were considered differentially expressed. As an 
alternate approach for normalization of gene and transcript level abundances, transcripts 
per million (TPM) were calculated using RSEM (v1.2.18) with default parameters.  
Gene expression heat maps  
For unsupervised hierarchical clustering and heat map generation, variance-stabilized 
expression values were clustered using average linkage with distance metric equal to 1 
minus the Pearson correlation coefficient using the 2000 genes with the most variable 
expression levels.  To visualize expression of specific genes involved in EMT, the log2 
ratio of normalized TPM values between paired mesenchymal (YFP+/Ecad-) and 
epithelial (YFP+/Ecad+) fractions from each individual tumor sample were plotted with 
ggplot2 in R. Markers specific for epithelial cells, mesenchymal cells and EMT 
transcription factors were selected from published literature86,92,159,180.   
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Comparison of human PDA cell lines  
Microarray expression data for human pancreatic cancer cell lines were obtained from 
the Cancer Cell Line Encyclopedia181.   
RNA extraction, cDNA synthesis and qPCR 
RNA was extracted using the RNeasy Micro kit (Qiagen) and cDNA was synthesized 
using the High Capacity cDNA Reverse Transcription kit (Thermofisher) according to the 
manufacturers’ instructions. qPCR was performed using SsoAdvanced Universal SYBR 
Green Supermix (Biorad) on a CFX384 Touch Real-Time PCR Detection System 
(Biorad) as previously described124. Relative expression was determined after adjusting 
for GAPDH.  
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Figure 3.1: Two distinct EMT programs exist in vivo. (a) Representative image of 
KPCY tumor stained for DAPI (blue), Yfp (red) and Ecad (green). Arrowheads denote 
cells that lack E-cadherin expression and have undergone EMT. Scale bar, 50 µm. (b) 
Experimental design. Primary KPCY tumors were dissociated, stained and sorted for 
Ecad. Epithelial (Yfp+/Ecad+) and mesenchymal (Yfp+/Ecad-) tumor cell populations were 
collected for transcriptome analysis. (c) Principal component analysis. (d) Hierarchical 
clustering. (e) Change in Ecad expression in canonical and non-canonical tumor pairs 
(log2 fold change Ecad- TPM/Ecad+ TPM). (f) Heat map of epithelial and mesenchymal 
transcripts in canonical and non-canonical tumor pairs (log2 fold change Ecad- 
TPM/Ecad+ TPM). TPM, transcripts per million. 
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Figure 3.2: Mesenchymal protein expression varies widely during EMT in vivo. (a-
d) Representative images of Ecad (left) and Zeb1 (a), Slug (b), Vim (c) and Fsp1 (d) 
expression (right); DAPI (blue), Yfp (red) and Ecad or mesenchymal marker (green). 
Scale bar, 50 µm. (e) Quantification of the percentage of mesenchymal marker-positive 
cells within the Yfp+/Ecad- putative EMT population. Bars represent mean ± SD.  
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Figure 3.3: RNAseq sorting quality controls. (a) Representative FACS plot of a KPCY 
tumor stained for Ecad. DP, double positive. (b) Representative images of tumor cells 
directly after sorting to check for purity. APC, allophycocyanin (fluorophore used for 
Ecad). (c-d) qPCR on sorted samples for CD45 (c), a leukocyte marker, and YFP (d) to 
rule out contamination of non-tumor cell populations. Bars represent mean ± SEM. 
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Figure 3.4: Gene set enrichment analysis (GSEA) reveals enrichment for EMT 
signatures in Ecad- samples.  
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Figure 3.5: EMT-TF expression differs between canonical and non-canonical EMT. 
Log2 fold change of Ecad- TPM/Ecad+ TPM in canonical and non-canonical tumors. 
TPM, transcripts per million. 
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Figure 3.6: EMT subtype correlates with histology. Hematoxylin and eosin (H&E) 
stained KPCY tumor sections.
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Figure 3.7: EMT subtype correlates with PDAC subtype. Hierarchical clustering of 
KPCY transcriptomes based on the Collisson (a), Bailey (b) and Moffitt (c) gene 
signatures for PDAC subtypes.  
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Figure 3.8: Cell lines segregate into canonical and non-canonical EMT. (a) 8-gene 
signature heatmap for KPCY tumor cell lines based on qPCR. (b) 8-gene signature 
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heatmap for established human PDAC cell lines based on expression data from the 
Cancer Cell Line Encyclopedia (CCLE). (c) Ecad expression (log2 fold change Ecad-
/Ecad+) of KPCY tumor cell lines sorted on Ecad. (d) Ecad expression (log2 fold change 
Ecad-/Ecad+) of human PDAC cell lines sorted on Ecad. (e) Principal component 
analysis of human PDAC cell lines based on whole transcriptome expression data from 
CCLE. (f) Principal component analysis of human breast cancer cell lines based on 
whole transcriptome expression data from CCLE.  
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Figure 3.9: Non-canonical cell lines are competent to undergo canonical EMT. (a) 
Representative phase contrast images of non-canonical cell line PD7591 ± Tgfβ 
treatment (5 ng/mL for 7d). Scale bars 100µm. (b) Expression of Tgfβ responsive genes 
± Tgfβ treatment normalized to GAPDH. (c) Western blot for E-cadherin ± Tgfβ 
treatment. 
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Figure 3.10: Non-canonical EMT is characterized by Ecad internalization. (a) 
Experimental design for acquiring protein from Ecad-sorted KPCY tumor cell lines. (b) 
Western blot for epithelial proteins on Ecad-sorted samples. (c) Experimental design for 
double Ecad labeling flow cytometry. (d) Quantification of the percentage of surface 
Ecad- cells with intracellular Ecad expression. (e-h) Confocal images of RNAseq tumor 
sections stained for DAPI (blue), Yfp (red) and Ecad (green). Scale bars 10µm. 
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Figure 3.11: Prrx1 regulates Ecad trafficking. (a) Prrx1 expression in non-
canonical RNAseq samples. (b) Surface expression of Ecad in non-canonical cell 
line PD7591 expressing control vector, Prrx1a, Prrx1b or Prrx1a/b (M-Ecad, 
Membranous Ecad). (c) Expression of intracellular Ecad (I-Ecad) in M-Ecad- cells 
in non-canonical cell line PD7591 expressing control vector, Prrx1a, Prrx1b or 
Prrx1a/b.  
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Figure 3.12: Non-canonical EMT confers enhanced tumor initiation potential and 
epithelial plasticity. (a) Limiting dilution assay results. Canonical and non-canonical 
KPCY tumor cell lines were sorted on Ecad and injected subcutaneously in NOD/SCID 
mice at 10,000; 1,000; 100; and 10 cells. (b) Tumor initiating cell (TIC) frequency, 
calculated using Extreme Limiting Dilution Analysis (ELDA) software182. (c) E-cadherin 
expression based on flow cytometry within unsorted and Ecad-sorted tumors from the 
limiting dilution experiment. Bars represent mean ± SD. P-values were calculated using 
Student’s T-test. *, p<0.05. 
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Antibody Dilution Vendor 
Rat α-Ecad 1:200-1:1000 Thermofisher & Takara Bio 
Rabbit α-Cldn7 1:100 Abcam 
Mouse α-p120 catenin 1:200 BD Biosciences 
Rabbit α-Slug 1:100 Gift of the Habener Lab 
Rabbit α-Zeb1 1:100 + TSA Santa Cruz Biotechnology 
Rabbit α-Vimentin 1:100 Cell Signaling Technology 
Rabbit α-Fsp1 1:500 Dako 
Mouse α-tubulin 1:5000 Sigma Aldrich 
 
Table 3.1: Antibodies used in Chapter 3.  
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CHAPTER 4: Conclusions and Future Directions 
 
Parallel evolution of a metastatic lesion and its attendant microenvironment 
 Throughout the study in Chapter 2, we focus on the development of the 
metastatic microenvironment in an autochthonous mouse model of pancreatic cancer. I 
found that single disseminated cells and small tumor cell clusters exhibit EMT features 
and lack an obvious tumor microenvironment, while larger lesions regain epithelial 
morphology and accumulate desmoplasia that closely resembles that of primary PDAC. I 
also observed that large metastases are hypovascular and poorly perfused while single 
cells and small lesions are well vascularized. Leukocyte populations did not show a 
strong association with metastatic lesions of any size but were increased overall in 
metastatic livers, especially macrophages and myeloid-derived suppressor cells 
(MDSCs). Adaptive immune cells such as T-lymphocytes were essentially absent from 
the metastatic microenvironment, consistent with the exclusion of this cell type from 
primary PDAC tumors. My results illustrate a gradual accretion of stroma and epithelial 
features during metastatic growth, and to my knowledge this is the first study describing 
the stepwise progression of spontaneous metastatic colonization. 
 The correlative nature of this work opens up many new potential avenues into the 
biology of metastasis. I focused entirely on dissemination to the liver because it is the 
most common site of PDAC metastasis, raising the question of whether metastases 
arise similarly at other locations. There is evidence that the clonality of metastasis differs 
within the liver and lung compared to the diaphragm and peritoneum, perhaps reflecting 
disparate selection pressures at different metastatic sites. In a similar mouse model of 
PDAC utilizing the Confetti allele as a lineage label, our lab demonstrated that gross liver 
and lung metastases exhibit reduced clonality with metastatic growth, while diaphragm 
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and peritoneal metastases remain polyclonal even at the macro-metastasis stage178. 
This suggests that metastatic development in the lung might have a similar progression 
to the liver, while diaphragm and peritoneal metastases likely develop along a different 
route.  
 Another question raised by this study is how stromal cells are recruited to sites of 
metastasis and what role they play in colonization. Myofibroblasts are essentially absent 
from the microenvironment of single cells and nano-metastases, but after the 10-cell 
stage they robustly accumulate at metastatic lesions suggesting that tumor cells secrete 
a recruitment factor that must reach a local threshold to function. Tumor-derived Sonic 
hedgehog (Shh) is a strong fibroblast mobilization signal in primary PDAC and likely 
plays a role in re-establishing the metastatic microenvironment76. Leukocytes such as 
macrophages and MDSCs do not accumulate at metastatic lesions specifically but are 
increased throughout metastatic livers, suggesting a systemic mechanism driving 
leukocyte trafficking to metastatic tissues. In melanoma, tumor-derived exosomes deliver 
long-range signals, specifically the Met receptor, to bone marrow progenitor cells, 
causing them to home to the liver and establish a pre-metastatic niche183. Similarly, 
PDAC-derived exosomes are taken up by resident macrophages of the liver (Kupffer 
cells), which in turn signal to local stellate cells to produce fibronectin which acts as a 
pre-metastatic niche31. So perhaps the increased numbers of macrophages and MDSCs 
are due to exosome-based recruitment to the liver, where they help to establish a 
generally permissive microenvironment for incoming metastatic cells. 
 Our observation that metastases become more epithelial with growth is 
consistent with the EMT/MET hypothesis, which postulates that EMT is required for early 
steps of metastasis (i.e. invasion and entry into the circulation) while MET is necessary 
for later steps (i.e. colonization). However, in our model it is impossible to discern 
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whether early mesenchymal lesions differentiate into epithelial ones or if early epithelial 
lesions are selected for within the liver microenvironment. Two recent studies of the role 
of EMT in metastasis would suggest that the latter possibility is true. Using two different 
mesenchymal Cre lines (Fsp1- and Vim-Cre) to lineage trace tumor cells that have 
undergone EMT in the Polyoma Middle T (PyMT) model of breast cancer, Fischer et al. 
found that lung metastases were uniformly negative for the EMT lineage label156. In other 
words, these metastatic cells had always been epithelial and never activated Fsp1 or 
Vim in their lifetime, suggesting that EMT is not required for metastasis. However, these 
two mesenchymal genes are almost certainly not universal EMT markers (none have 
been identified thus far), so it is possible that PyMT tumor cells undergo EMT through a 
different mechanism and therefore would be missed by this system. Furthermore, this 
study does not rule out the possibility that mesenchymal tumor cells are required for 
metastasis but only as chaperones for epithelial tumor cells in a phenomenon known as 
cell cooperation. During cell cooperation, tumor cell clones with different but 
complementary abilities work together to escape the primary tumor and metastasize184. 
In another study testing the role of EMT in metastasis, Zheng et al. knocked out Snail 
and Twist in the KPC model of PDAC and found no change in metastatic burden, again 
suggesting that EMT is not required for metastasis144. However, the authors failed to 
demonstrate that EMT is fully abrogated in these mice, and I found that Snail is 
expressed at high levels in both Ecad+ and Ecad- KPCY tumor cells in vitro and in vivo 
(Fig. 4.1), suggesting that it does not play a significant role in EMT in PDAC. Thus, it 
remains unclear whether EMT/MET or selection for epithelial cells occurs at metastatic 
sites. 
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EMT and response to chemotherapy 
The most surprising result from Chapter 2 is the observation that chemotherapy 
selects for epithelial tumor cells in vivo. I found that tumors subjected to long-term 
chemotherapy had a significantly lower frequency of EMT compared to untreated 
controls, and after a single dose of chemotherapy mesenchymal tumor cells exhibited 
higher rates of apoptosis than epithelial tumor cells. This is inconsistent with numerous 
reports that have linked EMT to chemoresistance144-146,156,185-187. However, these studies 
often possess one of two caveats (sometimes both): A. They were performed in vitro and 
thus lack the context of the tumor microenvironment or B. They rely on a single 
mesenchymal gene that might not be representative of the in vivo EMT program. Our 
data is consistent with at least one study which found that mesenchymal PDAC cell lines 
are sensitive to gemcitabine while epithelial PDAC cell lines are sensitive to erlotinib, an 
EGFR inhibitor17. It is likely that chemoresistance is dependent on the context. Cancer 
type, drug(s) used, and the microenvironment can all affect the delivery, metabolism and 
response to a given therapy. Further studies parsing these different contexts will be 
necessary to fully understand mechanisms of drug resistance in vivo. 
Discovery of an alternative mechanism of EMT in vivo 
 In Chapter 3, we focus on the mechanisms driving EMT in living tumors. I found 
that PDAC tumors can undergo EMT in one of two ways: through a canonical pathway 
involving transcriptional repression of epithelial genes, or through a non-canonical 
pathways involving post-translational repression of the epithelial program. PDAC 
subtype influences which mode of EMT tumor cells use, and there is evidence to 
suggest a similar correlation in breast cancer. Non-canonical EMT is characterized by 
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the internalization and cytoplasmic retention of epithelial proteins, which may contribute 
to their increased plasticity and tumor initiation potential. To my knowledge this is the 
first study to examine spontaneous cancer EMT in a physiologically relevant setting and 
the first to implicate post-translational regulation of the epithelial program as the 
predominant mechanism driving EMT in vivo. 
  There is some precedent for EMT regulation at the protein level during 
embryogenesis and in vitro. Snail is required during mouse gastrulation to 
transcriptionally repress Ecad, but is not sufficient to induce a full EMT: it must 
coordinate with p38, a mitogen-activated protein kinase (MAPK) that down-regulates 
Ecad protein without affecting transcription188. Epb41l5 is also required to down-regulate 
Ecad at the protein but not mRNA level during mouse gastrulation. It accomplishes this 
by disrupting the interaction between p120-catenin and Ecad, presumably exposing 
Ecad to ubiquitination by the E3 ubiquitin ligase Hakai, which facilitates Ecad 
internalization in association with Rab5+ early endosomes189. In Madine-Darby Canine 
Kidney (MDCK) cells, Gata6 promotes Ecad internalization and the formation of 
cytoplasmic Ecad+ punctae without effecting Ecad transcription, driving increased 
invasion190. It remains to be seen whether p38, Epb41l5 and Gata6 are involved in the 
same or parallel pathways and whether they play a role in cancer-associated EMT. 
In Chapter 3, we identified Prrx1 as a potential regulator of the non-canonical 
EMT phenotype, in particular with regard to Ecad trafficking. Both epithelial and 
mesenchymal isoforms of Prrx1 were significantly increased in non-canonical Ecad- 
tumor samples, leading us to pursue it as a candidate driver of NC-EMT. And while both 
isoforms promote the accumulation of cytoplasmic Ecad, they are not sufficient to down-
regulate membranous Ecad, a hallmark of EMT, suggesting that Prrx1 is a mediator but 
not a master regulator of NC-EMT. To identify a master regulator, we will most likely 
96 
 
have to focus on broad transcriptional changes rather than on individual differentially 
expressed genes within our dataset. One way to do this is to perform gene set 
enrichment analysis (GSEA) for transcription factor targets enriched within NC-EMT 
tumor samples191. At the top of the list in my preliminary analysis (Table 4.1) is Nuclear 
Factor of Activated T Cells (Nfat), which belongs to a calcium (Ca2+)-responsive family of 
transcription factors first discovered in the context of T-cell activation. Nfat proteins are 
regulated by calcineurin, which under Ca2+ replete conditions, dephosphorylates Nfat, 
allowing it to shuttle to the nucleus to modulate transcription192. Nfats have been 
implicated in PDAC progression and have been shown to promote tumor growth in 
PDAC through C-myc activation193,194 and p15INK4b repression195. Moreover, Nfat 
expression is associated with higher metastatic potential in colorectal cancer196. 
Therefore, based on GSEA and previous reports, Nfat would be a good candidate as a 
master regulator of NC-EMT in PDAC for future studies. 
The discovery of an alternative, post-translationally regulated EMT paradigm 
begs the question of whether epithelial-mesenchymal plasticity exists as a continuum 
rather than two discrete phenotypic states. In a recent comprehensive review article, 
Nieto et al. propose the idea of an intermediate EMT phenotypes of varying stability 
characterized by dampened epithelial characteristics with or without mesenchymal 
features86, reminiscent of the non-canonical EMT phenomenon described in Chapter 3. 
Furthermore, the authors acknowledge the inconsistency of mesenchymal qualities 
acquired during EMT and suggest the extent to which cells travel along the EMT 
continuum is highly context dependent86. We see evidence of this in Fig. 3.2, which 
demonstrates that traditional mesenchymal markers exhibit high inter- and intra-tumoral 
heterogeneity in the KPCY model. It is becoming increasingly clear that EMT is much 
more complex than previously thought: with so many EMT-inducing extracellular cues, 
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numerous signaling pathways, multiple layers of regulation and diverse molecular 
outputs, EMT can no longer be considered a simple binary switch between epithelium 
and mesenchyme.  
 
Concluding remarks  
 My thesis work was built upon the observation that pre-malignant pancreatic cells 
exhibit EMT features and are capable of seeding distant organs before frank 
malignancy. From there, it was a natural progression to study the cellular and molecular 
mechanisms of EMT and metastasis. This was made possible by the combination of a 
cancer model with lineage labeling, a technique borrowed from developmental biology.  
It is essentially impossible to identify tumor cells in situ that have undergone EMT 
without the aid of a lineage label, since they seamlessly blend in with true mesenchymal 
cells in the surrounding stroma. Furthermore, single disseminated cells and small 
metastatic lesions would be exceedingly difficult to locate within the vast parenchyma of 
the liver sans reporter. Without such a model, we would never know the events that take 
place during spontaneous metastatic colonization, nor would we learn that classical EMT 
mechanisms do not apply to the majority of PDAC tumors. This speaks to the power of 
animal modeling and the value of looking for innovative solutions in other fields. 
 Despite recent advances, many questions remain about the biology of EMT and 
metastasis. This work describes the stepwise progression of metastatic colonization but 
it stops short of uncovering the molecular requirements. Future studies will be necessary 
to address the mechanisms of stromal recruitment, metastasis-stroma crosstalk, the role 
of stroma in supporting colonization, and drug resistance of single disseminated cells. 
This work also revealed an alternative but predominant mode of EMT in living PDAC 
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tumors that challenges the paradigm of transcriptional regulation by EMT-TFs. However, 
it remains unclear what signals drive non-canonical EMT in vivo, what master regulators 
orchestrate it and what its molecular requirements are. It would also be interesting to find 
out whether the non-canonical EMT phenomenon is a general mechanism utilized by 
other cancer types. In Chapter 3, I presented evidence that well differentiated breast 
cancer cell lines fit the non-canonical EMT profile while poorly differentiated cell lines 
aligned with a canonical EMT expression pattern, however the true test will be to sort 
those cell lines on Ecad and perform qPCR to see how Ecad transcript behaves during 
EMT. Finally, a comparison of the metastatic potential of NC-EMT and C-EMT cells 
remains untested: perhaps NC-EMT cells are better equipped to metastasize because 
they retain both epithelial and mesenchymal properties and are thus more plastic. The 
answers to these questions will shed light on the metastatic process and expose its 
potential weaknesses, hopefully leading to a new generation of anti-metastatic therapies. 
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Chapter 4 Figures and Figure Legends 
 
 
Figure 4.1: Snail expression does not correlate with EMT in KPCY tumors. (a) 
KPCY tumor cell lines were sorted on Ecad and probed by Western blot for Snail. (b) 
KPCY tumor sections were stained for DAPI (blue), YFP (red), ECAD (white) and Snail 
(green). 
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Table 4.1: Enriched transcription factor targets in non-canonical Ecad- samples. 
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